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ABSTRACT OF THE DISSERTATION
HUMAN PAPILLOMAVIRUS INFECTION AND VACCINATION POLICIES IN
THE AMERICAN SOUTH
by
Dudith Pierre-Victor
Florida International University, 2016
Miami, Florida
Professor Purnima Madhivanan, Major Professor
In the United States, the South has a disproportionate burden of cervical cancer,
yet research reporting regional prevalence of human papillomavirus (HPV) infection is
scarce. Since 2008, Virginia has passed a HPV vaccine mandate and Louisiana a HPV
education bill. This dissertation estimated the prevalence of HPV infection among
females and assessed the impact of Virginia’s and Louisiana’s HPV vaccination policy on
vaccination among adolescent females.
The first manuscript estimated the prevalence of HPV infection using data from
4,250 females collected during the 2007–2010 National Health and Nutrition
Examination Survey. Among 14–26 year-olds, the prevalence of high-risk oncogenic
HPV was 25.6% (95% CI: 22.4 ̶ 33.3) in the South and 29.1% (95% CI: 24.8 ̶ 33.8) in the
rest of the country (p= 0.15). Among 27–59 year-olds, infection rates were 20.9% (95%
CI: 17.4 ̶ 24.9) for the South and 14.5% (95% CI: 12.9 ̶ 16.3) for the rest of the country
(p=0.0001).
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The second manuscript assessed the impact of Virginia’s HPV vaccine mandate
on vaccination using National Immunization Survey-Teen 2008-2012 data (n=3,203). A
difference-in-differences estimation and logistic regression analysis were performed with
South Carolina and Tennessee serving as comparison states. Virginia’s mandate was not
associated with an increase in vaccination rates. Physician recommendation was strongly
associated with vaccination in the Virginia-South Carolina (aOR=10.3; p=0.0001) and
Virginia-Tennessee analyses (aOR=9.33; 95%CI: 6.11 ̶ 14.3).
The third manuscript assessed the impact of Louisiana’s HPV education policy on
vaccination using difference-in-differences estimation and logistic regression analysis,
with Alabama and Mississippi as comparison states (n=2,327). There was no evidence
that the policy increased vaccination rates. Physician recommendation was associated
with vaccination in the Louisiana-Alabama (aOR=7.74; 95% CI: 5.22 ̶ 11.5) and
Louisiana-Mississippi comparison (aOR=7.05; 95% CI: 4.6 ̶ 10.5).
This study found a higher prevalence of HPV infection among females aged 27 ̶
59 years in the South compared to the rest of the country. Additionally, physician
recommendation was strongly associated with vaccination despite HPV policy
implementation. These findings highlight the importance of physician recommendation
for HPV vaccination and the need for recommended cervical cancer screening,
particularly in the South.
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Introduction
The southern region has long been known for its distinctiveness from the rest of
the country, as evidenced in a letter written by Thomas Jefferson in 1785 (Savitt &
Young, 1988). Several factors, including its unique Protestant Evangelical
Fundamentalism, contributed to that distinctiveness. One of the most salient
characteristics of the South is disease (Savitt & Young, 1988). Malaria, yellow fever,
typhoid fever, hookworm and pellagra were prevalent in the South compared to other
United States regions (Savitt & Young, 1988). In the Colonial years, these diseases took a
heavy toll on both poor white southerners as well as the large slave population on the
plantations. After the civil war, the South’s reputation for the poorest health in the nation
suppressed immigration and investment thereby further delaying social and economic
development (Savitt & Young, 1988). In the 21st century, the South continues to
maintain its distinctiveness. The proportion of individuals of Black/African descent in the
region since the time of slavery, rurality, poor socioeconomic living conditions, and
health disparities (Wimberley & Morris, 1996; Wimberly & Morris, 1997) being among
the principal factors contributing to its distinctiveness.
The South is comprised of 17 states: Delaware, District of Columbia, Florida,
Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, Alabama,
Kentucky, Mississippi Tennessee, Arkansas, Louisiana, Oklahoma and Texas (U.S.
Census Bureau, 2013b). A region of the South has also been identified as the Black Belt,
which spans across 11 states (Wimberley & Morris, 1996; Wimberly & Morris, 1997).
This particular region is comprised of counties with the percentage of African Americans
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ranging from 18.5% to 26.7% (Wimberley & Morris, 1996; Wimberly & Morris, 1997).
The Southern Black Belt is where Southern rurality, poor socio-economic conditions, and
health disparities meet. When the distribution of most chronic diseases—such as
cardiovascular diseases and diabetes—are mapped, the South or Sotheastern belt stands
out, indicating higher prevalence than the rest of the country (Barker, Kirtland, Gregg,
Geiss, & Thompson, 2011; Devesa et al., 1999; Lanska & Kuller, 1995).
Cervical cancer is among the chronic conditions that disparately plague the South
(Devesa et al., 1999; Howlader et al., 2013; U.S. Cancer Statistics Working Group,
2015). In 2010, the top ten states with the highest incidence and mortality rates for
cervical cancer were all located in the South (Howlader et al., 2013). In 2012, the
incidence of cervical cancer in the United States was 7.4 per 100,000 (U.S. Cancer
Statistics Working Group, 2015). Only Maryland, Virginia, North and South Carolina
had incidence rates below the national average. A similar geographic distribution is
reported for cervical cancer mortality (U.S. Cancer Statistics Working Group, 2015).
Human papillomavirus (HPV), the leading sexually transmitted infection (Cates,
1999; Weinstock, Berman, & Cates, 2004), has been consistently linked to oropharyngeal
and anogenital cancers (Bosch, Lorincz, Muñoz, Meijer, & Shah, 2002; Endo, Yamashita,
Jin, Akutsu, & Jimbow, 2003; Gissmann & zur Hausen, 1980; Jones, Rowan, & Stewart,
2005). The Food and Drug Administration had licensed the quadrivalent HPV vaccine
(HPV4, Gardasil) in 2006, which protects against HPV 6,11,16, and 18 (Centers for
Disease Control and Prevention, 2010b); the bivalent HPV vaccine (HPV2, Cervarix) in
2009, which confers protection against HPV 16 and 18 (Centers for Disease Control and
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Prevention, 2010a); and the nanovalent HPV vaccine (Gardasil9) in 2014, which confers
protection against HPV 6,11,16,18,31,33,45,52, and 58 (U.S. Food and Drug
Administration, 2014). The HPV vaccine has a three-dose schedule recommended for
boys and girls 11−12 years of age and catch-up vaccination for 13-26 year-olds (Centers
for Disease Control and Prevention, 2013a). Currently, HPV vaccines are administered in
primary health care settings (Herzog, Huh, & Einstein, 2010) including school-based
health care centers (Lofink et al., 2013).
Since the licensure of the vaccine, individual states have been enacting HPV
vaccination policies to address funding for HPV education or HPV vaccination (National
Conference of State Legislatures, 2015). Several states have passed bills requiring HPVrelated education and HPV vaccine awareness for adolescents, parents, or both. Indiana,
Utah, Iowa, New Jersey, and Washington took the lead on HPV and HPV vaccine
awareness legislatures in the 2006 ̶ 2007 period (National Conference of States
Legislatures, 2015). Among Southern states, only the District of Columbia and Virginia
had passed a HPV vaccine mandate for school-entry while North Carolina and Louisiana
required that schools provide HPV vaccine education to parents of preteens and teens in
specific grades (National Conference of State Legislatures, 2015). Virginia’s HPV
vaccine mandate requires girls entering sixth grade to receive at least one dose of the
HPV vaccine. Louisiana requires schools to provide HPV/HPV vaccine information to
parents of adolescents in grades 6 ̶ 12. Both policies were enacted in 2008 (National
Conference of State Legislatures, 2015).
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While HPV infection rates are available at the national level, there is a paucity of
research that examines geographic variation in HPV infection prevalence. Women
residing in the American South are disproportionately affected by cervical cancer.
However, research studies estimating HPV infection prevalence and those examining
socio-demographics and sexual behaviors associated with HPV infection are scarce. Such
information is crucial to increase cervical cancer prevention in order to reduce cancer
disparities.
Despite the availability of HPV vaccine for the last nine years, vaccination rates
are low among American adolescents (Centers for Diseases Control and Prevention,
2013). Vaccination rates are particularly low in the Southern region, notwithstanding its
high cervical cancer rates. In 2012, among 13-17 year-old females HPV vaccination rates
were lower in the South (48.9%) compared to the Midwest (50.5%), the Northeast
(58.2%), the West (61.4%), and the national average (53.8%) (Centers for Disease
Control and Prevention, 2013b). Virginia’s HPV vaccine mandate for school-entry and
Louisiana’s HPV vaccine awareness policies could serve as models for other Southern
states if they are effective. While several states have introduced similar HPV vaccine
awareness policies and HPV vaccine mandate for school-entry (National Conference of
State Legislatures, 2015), these policies have not been evaluated.
In light of cervical cancer disparities in the Southern region, the impact evaluation
of Virginia’s HPV vaccine mandate as a school-entry requirement and Louisiana’s HPV
vaccine education policies requiring HPV and HPV vaccine education for parents and
students is crucial. To contribute to this body of literature, the first manuscript estimated
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the prevalence of HPV infection in Southern region compared to the rest of the country.
Findings will shed light on the burden of HPV infection in the region in addition to
highlighting HPV infection disparities. Such information can guide national cervical
cancer prevention efforts to allocate limited resources to areas with greater needs. The
second manuscript assessed the impact of Virginia’s HPV vaccine mandate as a schoolentry requirement for girls in the sixth grade on HPV vaccination among 13 ̶ 17 year-old
females. The third manuscript assessed the impact of Louisiana’s law requiring HPV and
HPV vaccine education for parents and students on HPV vaccination among 13 ̶ 17 yearold females. HPV vaccine mandate for school-entry and HPV education legislature have
been introduced in several states (National Conference of State Legislatures, 2015).
Consequently, the impact assessment of both policies will shed light on whether parental
HPV awareness or HPV vaccine mandate for school-entry is effective to increase HPV
vaccination. Together, the second and the third manuscripts will provide policy-makers
with information that can assist them in deciding the best HPV vaccination policies.
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Manuscript 1
Human Papillomavirus Infections in the American South and Other United States
Regions
Abstract
Human papillomavirus (HPV) infection is the most common sexually transmitted
infection worldwide and has been linked to several cancers, including cervical cancer. In
the United States, the Southern region has a disproportionate burden of cervical cancer,
and research about the epidemiology of HPV in the region is scarce. This study estimates
the prevalence and correlates of HPV infections among 14–59 year-old females.
Data from 4,250 females aged 14–59 years collected during the 2007–2010
National Health and Nutrition Examination Survey were used. The prevalence of HPV
infection was estimated for the South, Northeast, Midwest, and West combined.
Weighted chi-square test and logistic regression were performed to examine the
association between HPV infection and socio- and behavioral demographics.
Among 14–26 year-old females, the prevalence of high-risk oncogenic HPV types
was 25.6% (95% confidence (CI): 22.4 ̶ 33.3) in the South and 29.1% (95% CI: 24.8 ̶
33.8) in the other regions (p= 0.15). Among 27–59 year-old women, infection with highrisk oncogenic types was 20.9% (95% CI: 17.4 ̶ 24.9) in the South compared to 14.5%
(95% CI: 12.9 ̶ 16.3) in other regions (p=0.0001).
This study found a higher prevalence of infection from high-risk oncogenic types
among 27 ̶ 59 year-olds. These findings indicate the importance of promoting HPV
vaccination as well as cervical cancer screening, particularly in the Southern region of the
United States.
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Background
Human papillomavirus (HPV) is the most common sexually transmitted infection
(STI) worldwide and has been consistently linked to head, neck, pharyngeal, and
anogenital cancers (Forman et al., 2012). Over 100 HPV types infect humans, with 40 of
these HPV types infecting mainly the anogenital tract (Franco, Duarte-Franco, &
Ferenczy, 2001). Most HPV-related cancers result from infections from HPV types 16
and 18 (Muñoz et al., 2003). According to their association with pre-malignancy and
invasive cancer, HPV types are classified as high- or low-risk oncogenic, and nononcogenic (Bosch et al., 2002; Franco et al., 2001; Wright, Denny, & Kuhn, 2000).
Cervical cancer is the fourth most common cancer worldwide and
disproportionately affects women in developing and underdeveloped countries. Among
HPV-related cancers, cervical cancer is the most prevalent. In developed countries,
cervical cancer affects poor and disadvantaged women (International Agency for
Research on Cancer, 2014). In the United States, cervical cancer mainly affects
disadvantaged, poor women with limited access to healthcare such as those living in the
Appalachian (Devesa et al., 1999; Horner et al., 2011), and the Southern regions (Devesa
et al., 1999). In 2010, the national cervical cancer incidence was 7.6 per 100,000. The
seven states with the highest cervical cancer incidence rates were all located in the South:
West Virginia (11.6 per 100,000), Arkansas (10.7), Oklahoma (10.3), Mississippi (10.2),
Washington D.C. (9.7), Texas (9.4), and Louisiana (9.1) (Howlader et al., 2013).
Women residing in the American South are disproportionately affected by
cervical cancer. However, research studies estimating prevalence of HPV infection and
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associated socio-demographic characteristics and sexual behaviors are lacking in the
region. Such information is crucial to increase HPV vaccination and cervical cancer
screening in order to reduce cancer disparities. The present study estimates the
prevalence of HPV infection from high-risk oncogenic, any oncogenic, and nononcogenic types and examines the correlates of HPV infections in the American South.
We hypothesized that the rates of infection from high-risk HPV types would be higher in
the South than in the rest of the United States.
Methods
Study Design and Population
The National Health and Nutrition Examination Survey (NHANES) data are
collected through a multifaceted probability sampling strategy in order to obtain a
representative sample of the noninstitutionalized population in the United States (Curtin,
Lester et al., 2013). NHANES detailed methodologies have been published elsewhere
(Curtin, Lester et al., 2013; Zipf et al., 2013). NHANES data collection occurs in two
stages: a home interview and a health examination. Upon selection, participants are first
screened to ensure eligibility. Eligible participants complete the home interview and are
invited to the Mobile Exam Center (MEC) for computer-assisted personal interview
(CAPI) questionnaires, audio computer-assisted personal self-interview (ACASI)
questionnaires, examinations, and biological specimen collection (Zipf et al., 2013).
From 2003 to 2010, females 14 ̶ 59 years are asked to self-collect vaginal
samples. Several studies have found self-collected vaginal swabs to be slightly less or as
sensitive as physician-collected samples (Bhatla et al., 2009; Ogoina, Musa, &
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Onyemelukwe, 2013; Petignat et al., 2007; Zhao et al., 2012). A systematic review
comparing self-collected and physician-collected samples for low- and high-risk types
HPV DNA detection from 18 studies estimated the average detection rate at 27.4% (26.228.6) for self-sampling and 28.0% (26.8-29.1) for physician-sampling (Petignat et al.,
2007). NHANES reports HPV test results as positive, negative, inadequate or missing for
40 HPV types.
Two NHANES survey cycles, 2007 ̶ 2008 and 2009 ̶ 2010, were combined to
maximize the sample for the analysis. A total of 4,250 females aged 14 ̶ 59 years
provided adequate self-collected vaginal samples for HPV DNA detection from 2007 to
2010. Based on HPV vaccine eligibility, the sample was divided into those still eligible
for HPV vaccine (14 ̶ 26 years) and those no longer eligible for HPV vaccine (27 ̶ 59
years).
Variables
HPV infection status was the outcome of interest. Following the classification
scheme developed by several researchers (Bosch et al., 2002; Bouvard et al., 2009;
Franco et al., 2001), HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 were
classified as high-risk oncogenic types. HPV types 6, 11, 16, 18, 31, 33, 35, 39, 40, 42,
45, 51, 52, 53, 55, 56, 58, and 59 were classified as oncogenic types. The remaining HPV
types were classified as non-oncogenic.
Socio-demographic variables from the home interview survey, sexual behavior
variables from the ACASI questionnaires, reproductive health variables from the CAPI
questionnaires, and HPV infection status from the laboratory data were merged for the
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analysis. HPV infection status, race/ethnicity, country of birth, country of citizenship,
federal poverty level, health insurance status, healthcare utilization variables, HPV
infection status, use of contraception, duration of contraception use, age at first sexual
intercourse, and number of lifetime partners were included in the analysis. Females who
tested positive for at least one of the high-risk oncogenic types were classified as being
infected from high-risk oncogenic HPV types. The same criterion was used for any
oncogenic types. Since the region and state of residence are restricted variables, the
dataset was accessed and analyzed at the Restricted Data Center (Atlanta, GA).
Furthermore, to prevent potential disclosure, the region rather than the state of residence
of survey respondents was specified in the dataset.
Statistical Analysis
STATA svy (StataCorp, 2013) commands were used to conduct the analyses to
account for the complex multistage study design and sample weight. Since two survey
cycles were combined, NHANES guidelines were followed to compute the new MEC
sample weight used in the analysis. Women 14 ̶ 59 years of age from all racial/ethnic
groups were included in the analysis. The proportion of respondents who tested positive
for high-risk oncogenic, any oncogenic, and non-oncogenic HPV types for 2007 ̶ 2010
were computed for the South separately and the three other regions combined (Northeast,
Midwest, and West). A 95% confidence interval was computed for each proportion.
Weighted chi-square analyses were performed to examine the association between HPV
infection and important demographic, healthcare utilization, and sexual behavior
variables. Variables that were significantly associated with HPV infection from high-risk
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oncogenic and any oncogenic type HPV and sexual behavior variables were included in a
multivariable logistic regression to identify factors independently associated with HPV
infection among sexually active women. We performed analysis with all females for
whom the variables of interest were present. A 5% significance level was used for all
analyses.
Results
HPV Prevalence
14–26 year-old females
The prevalence of high-risk oncogenic types was 25.6% (95% CI: 22.4 ̶ 33.3) in
the South and 29.1% (95% CI: 24.8 ̶ 33.8) in the rest of the U.S. (p=0.15). The
prevalence of any oncogenic type was 31.7% (95% CI: 26.4 ̶ 37.6) in the South and
32.3% (95% CI: 27.9 ̶ 36.9) in other regions (p=0.84). Non-oncogenic type prevalence
was 36.5% (95% CI: 30.0 ̶ 43.4) in the South and 31.9% (95% CI: 26.9 ̶ 37.4) in the other
regions (p=0.08) (Table 1).
27-59 year-old women
Infection with high-risk oncogenic types was 20.9% (95% CI: 17.4 ̶ 24.9) in the
South compared to 14.5% (95% CI: 12.9 ̶ 16.3) in other regions (p=0.0001). For
infection from any oncogenic types, infection rates were 24.0% (95% CI: 19.9 ̶ 28.7) and
17.9% (95% CI: 16.3 ̶ 19.5) for the South and other regions respectively (p=0.0001)
(Table 1).
[Table 1 Here]
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Demographics Associated with HPV Infection
14–26 year-old females
In the South, infection from high-risk oncogenic type HPV varied significantly by
race/ethnicity, history of contraceptive use, sexual activity status, and number of lifetime
sex partners (Table 2). Among women living in the rest of the country, infection with
high-risk oncogenic types differed by marital status, poverty index, insurance status,
history of contraceptive use, sexual activity status, number of lifetime sex partners, and
having had at least one sex partner five years older (Table 2). In the South, infection from
any oncogenic types varied by race/ethnicity, history of contraceptive use, sexual activity
status, and number of lifetime sex partners (Table 3). In the rest of the country, infection
from any oncogenic types varied by marital status, insurance status, history of
contraceptive use, sexual activity status, and number of lifetime sex partners (Table 3).
[Table 2 Here]
[Table 3 Here]
27–59 year-old women
In the Southern region, infection from high-risk oncogenic HPV types varied
significantly by race/ethnicity, country of birth, marital status, poverty index, insurance
status, and number of lifetime sex partners (Table 4). Among women living in other US
regions, infection from high-risk oncogenic types differed by race/ethnicity, marital
status, poverty index, insurance status, type of place one receives care, healthcare
utilization, age at first sexual intercourse, number of sex partners 5 years or older, and
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number of lifetime sex partners (Table 4). For the Southern region, infection from any
oncogenic types varied by race/ethnicity, country of birth, marital status, poverty index,
insurance status, and number of lifetime sex partners (Table 5). In the rest of the country,
infection from any oncogenic types differed by race/ethnicity, marital status, poverty
index, type of place respondents receive care, age at first sexual intercourse, number of
lifetime sex partners, and having had at least one sex partner five years older (Table 5).
[Table 4 Here]
[Table 5 Here]
Correlates of HPV Infection among Sexually Active Women
14–26 year-old females
Among 14–26 year-old females in the South, those whose income was 300–499%
above the federal poverty level had lower odds of infection from high-risk HPV
oncogenic types compared to those whose income was below the federal poverty level
(adjusted odds ratio (aOR)= 0.36; p< 0.01). Additionally, females who had four or more
lifetime sex partners had greater odds of infection with high-risk oncogenic types
compared to those who had three or fewer sex partners (aOR= 8.27; p<0.001) (Table 6).
Among 14–26 year-old females living in other regions, those who have never been
married had greater odds to be infected from high-risk oncogenic types compared to
those who were married (aOR= 12.79; p<0.001), and those who were divorced or
separated had higher odds of infection (aOR= 6.09; p<0.001) (Table 6).
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For infection with any oncogenic types in the South, females whose income was
200–499% above the poverty index had lower odds of infection compared to those whose
income was below the poverty index (aOR= 0.45; p<0.05) (Table 6). Southern females
who had insurance coverage had higher odds of infection compared to those who had no
coverage (aOR=2.48; p<0.01). Those who had four or more sex partners had higher odds
of infection compared to those who had three or fewer partners (aOR=8.51; p<0.001).
Among females in other regions, those who had never been married had greater odds to
be infected with high-risk oncogenic types compared to those who were married (aOR=
14.1; p<0.001), and those who were divorced or separated had higher odds of infection
(aOR= 6.13; p<0.001). Additionally, females who had four or more sex partners had
higher odds of infection compared to those who had three or fewer sex partners
(aOR=4.40; p<0.001) (Table 6).
[Table 6 Here]
27–59 year-old females
Among 27–59 year-old women in the South, those who had never been married
had increased odds to be infected with high-risk oncogenic types (aOR= 5.14; p<0.01),
and the odds were also higher for those who were no longer married (aOR=2.98; p<0.05)
compared to married women (Table 7). In the other regions, women who had never been
married (aOR= 2.38; p<0.01) and those who were previously married (aOR= 4.26;
p<0.05) had higher odds of infection from high-risk oncogenic types. Women with
household income 300–499% above the poverty index had lower odds to be infected
(aOR= 0.26; p<0.01). Additionally, women who had one or more sex partners at least
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five years older (aOR= 1.82; p<0.01) and who had four or more sex partners (aOR= 3.78;
p<0.01) had greater odds to be infected (Table 7).
For any oncogenic types, in the South, women who had never been married had
higher odds of infection (aOR= 4.27; p<0.01). In the rest of the country, women who had
never been married had greater odds to be infected (aOR= 2.20; p<0.01) and those who
were divorced, separated, or widowed also had increased odds to be infected (aOR= 4.16;
p<0.01). Women whose income was 300–499% above the poverty index had lower odds
of infection from any oncogenic types (aOR= 0.46; p<0.01). Those who had four or more
sex partners had higher odds of infection (aOR= 3.90; p<0.001), and those who had their
sexual debut at 15 years or older had lower odds to be infected from any oncogenic types
compared those who had their sexual debut at 14 years or younger (aOR= 0.47; p<0.01)
(Table 7).
[Table 7 Here]
Discussion
Cervical cancer is more prevalent in the Southern region compared to the rest of
the United States, and this study found that the prevalence of HPV infections from highrisk oncogenic types was higher in the South than the rest of the United States, among
women aged 27 ̶ 59 years but not among those 14 ̶ 26 years old. Among 14 ̶ 26 year-old
females, having four or more lifetime sex partners was positively associated with
infection from high-risk and any oncogenic types infection in the South and the rest of
the country. Among 27 ̶ 59 year-old females, having four or more lifetime sex partners
was positively associated with infection from high-risk and any oncogenic types infection
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in the rest of the country but not in the South. Moreover, sexually active women who
have never been married and those who were divorced, separated, or widowed to have a
greater odds of infection from any oncogenic and high-risk oncogenic types.
The prevalence of infection from high-risk oncogenic types was higher in the
South compared to the rest of the U.S. among 27 ̶ 59 year-old females. Although there is
limited literature investigating geographic variation in HPV infection, a study estimated
HPV prevalence among women in the Appalachia, a region with high rates of cervical
cancer and predominantly non-Hispanic White population (Reiter, Katz, Ruffin, et al.,
2013). The study found higher prevalence of high-risk infection among Appalachian
women (Reiter, Katz, Ruffin, et al., 2013) when compared to the national estimates for
non-Hispanic White females (Hariri et al., 2011). The majority of the Appalachian
women were between the ages of 18 and 40 years (Reiter, Katz, Ruffin, et al., 2013). The
difference in the prevalence of infection from high-risk oncogenic types in the South
compared to the rest of the U.S. among 27 ̶ 59 year-old females appears to be smaller
than the difference in cervical cancer incidence and mortality. Therefore, this difference
in the prevalence is not large enough to account for the higher prevalence of cervical
cancer in the South.
Among 14 ̶ 26 year-olds, the prevalence of infection from high-risk oncogenic or
any oncogenic types HPV was not higher in the South compared to the rest of the
country. Using the 2003 ̶ 2006 and the 2007 ̶ 2010 NHANES survey cycles, a study
investigated the change in the prevalence of infection from HPV types 6, 11, 16, or 18
(Markowitz et al., 2013). Among females aged 14 ̶ 19 years, HPV infection prevalence
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declined from 11.5% in the 2003 ̶ 2006 cycle to 5.1% in the 2007 ̶ 2010 cycle. Similar
decline was not observed in the older age-groups (Markowitz et al., 2013). Comparable
rates of infection from high-risk or any oncogenic types between the South and the rest of
the country among 14 ̶ 26 year-olds are probably due to the national decline in HPV
infection in the vaccine-eligible age-group.
Among 14 ̶ 26 year-old females, this study found that having four or more
lifetime sex partners was positively associated with infection from high-risk and any
oncogenic types in the South and the rest of the country. However, among 27 ̶ 59 yearold females, having four or more lifetime sex partners was positively associated with
infection from high-risk and any oncogenic types in the rest of the country but not in the
South. Previous research has reported that increasing number of lifetime sex partners was
associated with HPV infection (Dunne et al., 2007; Markowitz et al., 2009; Reiter, Katz,
Ruffin, et al., 2013). It is not clear as to why increasing number of sex partners was not
associated with infection from high-risk or oncogenic types in the South.
The present study also found sexually active women who had never been married
and those who were divorced, separated, or widowed had greater odds of infection from
any oncogenic and high-risk oncogenic types. Several studies have reported higher
prevalence of HPV infection among unmarried women (Dunne et al., 2007; Kahn et al.,
2007; Reiter, Katz, Ruffin, et al., 2013). The absence of a long-term and committed sex
partner facilitates multiple sexual partnerships or short-term sexual partnerships, which
increase the risk of HPV infection. This may help explain the higher prevalence of
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infection from high-risk and any oncogenic types observed among unmarried sexually
active women.
The results indicated that the prevalence of infection from high-risk oncogenic
types was higher in the South compared to the rest of the U.S. among 27 ̶ 59 year-old
females. Public health efforts to increase cervical cancer screening in the South as well as
efforts to increase HPV vaccination among vaccine-eligible females must continue in
order to decrease the disparities in cervical cancer mortality. Healthy People 2020’s goal
is to increase the proportion of 21–65 year-old women who receive a cervical cancer
screening based on the most recent guidelines to 93% (U.S. Department of Health and
Human Services, 2014). In 2013, 78.5% of women aged 21 ̶ 65 years had a pap smear test
in the past three years (National Institute of Health, 2015). This report found lower
cervical cancer screening rates among women living 200% or below the poverty index
and among women who had less than high school education (National Institute of Health,
2015). Doescher and colleagues reported that women with low socio-economic status,
particularly those residing in rural areas, were less likely to be screened for cervical
cancer (Doescher & Jackson, 2009). Thus, Southern women of low socio-economic
status, especially those living in rural areas, should be targeted for cervical cancer
screening.
The present study had several limitations. First, sexual behaviors were selfreported, which inevitably lends to poor recall and social desirability bias. Sexual
behavior is generally considered a private and sensitive matter. As a result, most
individuals are not enthusiastic about revealing their sexual practices due to social
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stigma, embarrassment, or loss of confidentiality (Brener, Billy, & Grady, 2003; Kelly,
Soler-Hampejsek, Mensch, & Hewett, 2013; O’Sullivan, 2008). Consequently, such
behaviors may be underrepresented. In the same vein, previous research has reported that
responses to ACASI collecting sexual behavior data are generally more accurate
compared to face-to-face interviews (Ghanem, Hutton, Zenilman, Zimba, & Erbelding,
2005; Phillips, Gomez, Boily, & Garnett, 2010). NHANES collects sexual behavior data
using ACASI thereby reducing social desirability bias in this study. Moreover, the
vaginal swabs were self-collected, and HPV testing could not be performed for some
respondents due to inadequate specimen collection. However, this study also had several
strengths. First, the study used a nationally representative sample which is robust against
selection bias. Additionally, NHANES accounts for participant non-response. As a
result, these aspects lends to more reliable and valid findings. Moreover, the present
study is among the few to have attempted to assess the prevalence of infections from high
and low-risk HPV among 14 ̶ 59 year-old women in a region with a disparate cervical
cancer burden.
Conclusion
This study estimated the prevalence of infection among females for the South and
the rest of the country and found a higher prevalence of infection from high-risk
oncogenic and any oncogenic HPV types among 27 ̶ 59 year-old Southern females
compared to the rest of the country, but not among the 14 ̶ 26 year-olds. Women in the
Southern region remain at higher risk of developing and dying from cervical cancer, and
the higher prevalence of infection from high-risk oncogenic and any oncogenic HPV
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types among 27 ̶ 59 year-olds in the South partially explains the higher prevalence of
cervical cancer in the South. However, the difference in HPV prevalence in the older
age-group seems to be smaller than the difference in cancer incidence between the South
and other regions. This suggests that the disparities in cervical cancer incidence are not
only being driven by the differences in the epidemiology of HPV alone, but also by
disparities in cervical cancer screening. Efforts to make cervical cancer screening
accessible to disadvantaged women in the region must continue in order to reduce
disparities in cervical cancer mortality.
Among 14 ̶ 26 year-olds, the prevalence of infection from high-risk oncogenic
and any oncogenic types HPV was relatively high in the South and the rest of the
country. These findings reiterate the need for HPV vaccination to be administered to preteens, prior to their sexual debut. Additionally, females aged 14 ̶ 26 years are still eligible
for HPV vaccination catch-up. Consequently, healthcare providers should recommend the
vaccine to 14 ̶ 26 year-old females even if they are already infected with one HPV type as
they can be protected from other HPV types covered by the vaccine.
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Tables
Table 1. Prevalence of high-risk oncogenic, oncogenic, and non-oncogenic types
HPV
Regiona
South (n=532) Otherb (n=811)

14-26 year-old females
High-risk oncogenicc types infection

p-value
0.15

Yes 25.6 (22.4-33.3)
No 74.4 (66.7-77.5)

29.1 (24.8-33.8)
70.9 (66.2-75.2)

Any oncogenicd types infection

0.84
Yes 31.7 (26.4-37.6)
No 68.3 (62.4-73.6)

32.3 (27.9-36.9)
67.7 (63.0-72.1)

Non-oncogenice types infection

0.08

Yes 36.5 (30.0-43.4) 31.9 (26.9-37.4)
No 63.4 (56.6-69.9) 68.1 (62.6-73.1)
27-59 year-old females
South (n=1,066) Other b (n=1841)
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High-risk oncogenicc types infection
0.0001
Yes 20.9 (17.4-24.9) 14.5 (12.9-16.3)
No 79.1 (75.1-82.6) 85.5 (83.7-87.1)
d
Any oncogenic types infection
0.0001
Yes 24.0 (19.9-28.7) 17.9 (16.3-19.5)
No 76.0 (71.3-80.1) 82.1 (80.5-83.7)
Non-oncogenice types infection
0.014
Yes 32.4 (29.6-35.4) 28.1 (26.3-30.1)
No 67.6 (64.6-70.4) 71.9 (69.9-73.7)
a
To prevent potential disclosure, the region rather than the state of residence was included
in the dataset
b
c

Northeast, West, and Midwest combined

HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59

d

HPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 58, and 59

e

All other HPV types

Table 2. Socio-demographic and behavioral characteristics associated with infection
from high-risk types among 14-26 year-old females
Characteristics

a

Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Other
Country of birth
US
Other
Country of citizenship
US
Other
Marital Status
Married
Never married 2

HR Oncogenica types
South (n= 532 )
Otherb regions (n=811)
Infection
p-value
Infection
p-value
Status
Status
Yes
No
Yes
No
%
%
%
%
0.04
0.2
44.2
55.7
65.6
63.0
34.2
19.0
11.4
8.9
21.6
25.3
23.0
28.1
0.28
0.7
89.9
88.0
86.5
88.4
10.1
12.0
13.5
11.6
0.58
0.9
93.8
92.0
91.7
91.6
6.2
7.4
8.3
8.4
0.5
0.00001
22.5
31.3
4.8
25.2
65.3
65.3
69.3
53.2
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Divorced/separated/cohabitating
Income to federal poverty level

12.2

<100%
100-299%
300-499%
≥ 500%

35.6
22.8
27.4
14.2

13.1

25.9

21.6

0.45
25.2
25.5
30.8
18.5

Health insurance

0.03
26.1
23.6
29.1
21.2

24.4
20.1
24.4
31.1

0.55

Yes
No
Type of place most often go for
healthcare
Doctor's office
Other
No. of times receive healthcare
last year

69.1
30.9

None
≤3
≥4
Ever taken birth control pills

10.4
57.2
32.4

Yes
No

70.2
29.8

74.3
25.7

0.036
68.3
31.7

79.3
20.7
0.7

0.39
60.3
39.7

66.9
33.1

74.0
26.0

71.8
28.2
0.8

0.69
13.2
52.2
34.6

12.2
50.1
37.7

10.8
52.2
37.0

0.005
45.6
54.4

No. of years of birth control
pills

0.0001
62.2
37.8

42.5
57.5
0.5

0.51
<2
≥2

43.2
56.8

47.6
52.4

Ever had sexe

44.4
55.6

50.8
49.2

0.00001

Yes
No
Age at first sexual intercourse

95.5
4.5

9-14 years
>= 15 years
No. of lifetime sex partners
≤3
≥4
No. of sex partners 5+ years
older
None
≥1

23.8
76.2

67.1
32.9

0.00001
95.0
5.0

62.7
37.3
0.6

0.96
23.9
76.1

25.5
74.5

22.4
77.6

0.00001
20.5
79.5

66.3
33.7

0.00001
27.3
72.7

64.7
35.3
0.002

0.52
71.1
28.9

75.8
24.2
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59.0
41.0

75.9
24.1

a

HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59

b
a

HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59

b
c

Northeast, West, and Midwest combined

HPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 58, and 59

Northeast, West, and Midwest combined

Table 3. Socio-demographic and behavioral characteristics associated with infection
from any oncogenic types among 14-26 year-old females
Characteristicsa

Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Other
Country of birth
US
Other
Country of citizenship
US
Other
Marital Status
Married
Never married
Divorced/separated/cohabitating
Income to federal poverty level
<100%
100-299%
300-499%
≥ 500%

Any oncogenica HPV types
South (n= 532 )
Otherb regions (n=811)
Infection
p-value
Infection
p-value
Status
Status
Yes
No
Yes
No
%
%
%
%
0.015
0.14
43.6
56.7
65.6
62.8
34.4
18.0
11.7
8.7
22.0
25.3
22.7
28.5
0.15
0.8
90.8
87.4
87.4
88.0
9.2
12.8
12.6
12.0
0.6
94.4
92.2
0.35 92.3
91.3
5.6
7.8
7.7
8.7
0.5
0.00001
23.4
31.6
5.1
26.7
64.2
55.3
69.4
51.7
12.4
13.1
25.5
21.6
0.3
0.3
36.2
21.9
29.6
12.3

24.3
26.1
29.9
19.7

Health insurance
Yes
No
Type of place most often go for
healthcare

26.6
23.8
27.5
22.1

24.0
19.8
25.0
31.2

0.6
70.3
29.7

74.0
26.0
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0.02
67.6
32.4

0.13

80.2
19.8
0.8

Doctor's office
Other
No. of times receive healthcare
last year

56.6
43.4

None

11.9
54.7
33.4

≤3
≥4

69.0
31.0

71.6
28.4

72.8
27.2

0.92
12.7
53.1
34.2

Ever taken birth control pills

0.5
12.9
48.8
38.3

10.3
53.0
36.7

0.0005

Yes
No

69.8
30.2

44.4
55.6

No. of years of birth control
pills

0.0001
63.3
36.7

41.2
58.8

0.11
<2
≥2

41.8
58.2

48.9
51.1

Ever had sexe
Yes
No
Age at first sexual intercourse

0.8
44.2
55.8

51.4
48.6

0.00001
95.2
4.8

65.7
34.3

0.00001
95.4
4.6

0.8

61.2
38.8
0.5

9-14 years
23.1
24.3
25.4
22.2
>= 15 years
76.9
75.7
74.6
77.8
No. of lifetime sex partners
0.00001
0.00001
≤3
22.0
68.9
27.0
67.0
≥4
78.0
31.1
73.0
33.0
No. of sex partners 5+ years
0.08
0.001
older
None
68.3
78.1
59.2
76.9
≥1
31.7
21.9
40.8
23.1
a
HPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 58, and 59
b

Northeast, West, and Midwest combined
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Table 4. Socio-demographic and behavioral characteristics associated with infection
from high-risk oncogenic types among 27-59 year-old females
Characteristics

Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Other
Country of birth
US
Other
Country of citizenship
US
Other
Marital Status
Married
Never married
Divorced/separated/cohabitati
ng
Income to federal poverty
level
<100%
100-299%
300-499%
≥ 500%
Health insurance
Yes
No
Type of place most often go
for healthcare
Doctor's office
Other
No. of healthcare visits last
year
None

HR Oncogenica types
South (n= 1,066 )
Other regions (n=1841)
Infection
p-value
Infection
p-value
Status
Status
Yes
No
Yes
No
%
%
%
%
0.017
0.004
57.9
59.0
64.8
73.1
26.1
18.9
13.8
7.3
16.0
22.1
21.5
19.6
0.9
0.04
91.0
83.2
82.4
82.1
9.0
16.8
17.6
17.9
0.06
0.6
93.5
90.6
91.3
90.2
6.5
9.4
8.7
9.2
0.0000
0.00001
1
38.1
66.6
36.1
65.9
18.4
8.9
20.3
11.4
43.5
24.5
43.6
22.7
0.008
27.9
22.3
27.7
22.1

16.8
21.5
26.8
34.9

0.0002
21.9
22.1
19.9
36.1

10.9
16.6
28.9
43.6

0.006
64.2
35.8

76.9
23.1

0.02
79.2
20.8

85.6
14.4

0.7
76.1
23.9

77.5
22.5

0.01
71.0
29.0

77.3
22.7

0.5
14.9

12.0
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0.041
13.3

12.0

a

≤3
≥4
Ever taken birth control pills
Yes
No
No. of years of birth control
pills
<2
≥2
Ever had sexe
Yes
No
Age at first sexual intercourse

47.8
37.3

9-14 years
>= 15 years
No. of lifetime sex partners
≤3
≥4
No. of sex partners 5+ years
older
None
≥1

17.3
82.7

13.9
86.1

21.8
78.2

38.7
61.3

48.8
39.2

55.5
31.2

48.5
39.5

0.97
83.7
16.3

83.6
16.4

0.43
84.8
15.2

82.8
17.2

0.15
30.6
69.4

25.0
75.0

0.04
34.1
65.9

25.2
74.8

0.15
98.2
1.8

98.3
1.8

0.14
98.8
1.2

97.7
2.3

0.47

0.016
14.1
85.9

9.9
90.1

20.3
79.7

41.4
58.6

0.00001

0.0004

0.17
58.1
41.9

72.7
27.3

0.0002
58.4
41.6

75.2
24.8

HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59

b

Northeast, West, and Midwest combined

Table 5. Socio-demographic and behavioral characteristics associated with infection
from any oncogenic types among 27-59 year-old females
Characteristics

Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Other
Country of birth
US

Any oncogenica HPV types HPV
South (n=1,066)
Otherb regions (n= 1,841)
Infection
p-value
Infection
p-value
Status
Status
Yes
No
Yes
No
%
%
%
%
0.02
0.015
56.9
59.4
66.4
73.1
25.9
18.6
12.5
7.3
17.2
22.0
21.2
19.6
0.02
0.7
90.8
82.9
83.7
81.9
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Other

9.2

17.1

Country of citizenship

16.3

18.1

0.15
US
Other

93.3
6.7

90.5
9.5

Marital Status
Married
Never married
Divorced/separated/cohabitati
ng
Income to federal poverty
level
<100%
100-299%
300-499%
≥ 500%
Health insurance
Yes
No
Type of place most often go
for healthcare
Doctor's office
Other
No. of healthcare visits last
year
None
≤3
≥4
Ever taken birth control pills
Yes
No
No. of years of birth control
pills
<2
≥2
e
Ever had sex
Yes
No
Age at first sexual intercourse
9-14 years
>= 15 years

0.32
92.0
8.0

90.0
10.0

0.0000
1
39.6
18.1
42.3

67.4
8.6
24.0

0.00001
40.1
17.4
42.4

66.2
11.7
22.1

0.006
27.2
23.3
28.1
21.4

16.5
21.2
26.6
35.6

0.001
20.0
21.3
21.3
37.4

10.9
16.5
29.0
43.6

0.004
64.0
36.0

77.5
22.5

0.05
80.8
19.2

85.5
14.5

0.4
74.8
25.2

77.9
22.1

0.01
71.6
28.4

77.5
22.5

0.8
13.6
48.5
37.9

12.3
48.6
39.1

0.4
12.4
52.9
34.8

12.2
48.7
39.1

0.9
83.2
16.8

83.7
16.3

0.9
83.3
16.7

83.1
16.9

0.2
30.4
69.6

24.9
75.1

97.9
2.1

97.4
2.6

0.08
32.6
67.4

25.2
74.8

98.6
1.4

97.7
2.3

0.5

0.2

0.3
18.0
82.0

13.5
86.5

32

0.0003
15.5
84.5

90.6
9.2

No. of lifetime sex partners

0.004

0.00001

≤3 21.7
39.4
21.6
42.0
≥4 78.3
60.6
78.4
58.0
No. of sex partners 5+ years
0.3
0.003
older
None 62.0
71.9
60.2
75.6
≥1 38.0
28.1
39.8
24.4
a
HPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 58, and 59
b

Northeast, West, and Midwest combined

Table 6. Odds of HPV infections among sexually active 14 ̶ 26 year-old females by
socio-demographic and sexual behavioral characteristics
Characteristics

Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Other

HRa onocogenic types HPV
South
Otherc
d
aOR
aOR

Any oncogenicb types HPV
South
Otherc
aOR
aOR

Ref.
1.79 (0.625.2)
1.21 (0.562.6)

Ref.
0.85 (0.352.1)
0.73 (0.391.4)

Ref.
1.73 (0.744.0)
1.32 (0.602.94)

Ref.
1.09 (0.472.6)
0.69 (0.401.19)

Ref.
1.56 (0.445.5)
1.62 (0.475.5)

Ref.
12.79(4.834.1)***
6.09
(2.2=16.6)**
*

Ref.
1.33 (0.181.4)
1.41 (0.365.5)

Ref.
14.1 (6.331.4)***
6.13 (2.415.8)***

Ref.
0.59 (0.251.4)
0.36 (0.170.75)**
0.52 (0.132.2)

Ref.
1.79 (0.516.2)
1.59 (0.653.9)
1.01 (0.313.2)

Ref.
0.50 (0.171.4)
0.41 (0.170.99)*
0.36 (0.071.9)

Ref.
2.18 (0.598.0)
1.32 (0.573.1)
1.16 (0.413.3)

Ref.
2.17 (0.795.9)

Ref.
0.66 (0.271.6)

Ref.
2.48 (1.235.02)**

Ref.
0.60 (0.241.51)

Marital Status
Married
Never married
Divorced/separated/co
habitating
Federal poverty level
<100%
100-299%
300-499%
≥ 500%
Health insurance
No
Yes

33

No. of sex partners 5+
years older
None
≥1

Ref.
0.65 (0.241.8)

Ref.
1.32 (0.662.7)

Ref.
0.94 (0.441.97)

Ref.
1.43 (0.683.0)

Ref.
Ref.
Ref.
8.27 (2.84.03 (2.28.51 (3.724.4)***
7.4)***
19.6)***
a
HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59

Ref.
4.40 (2.48.2)***

No. of lifetime sex
partners
≤3
≥4

b

HPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 58, and 59

c
d

Northeast, West, and Midwest combined

adjusted odds ratio

*p<0.05; ** p<0.01; *** p<0.001

Table 7. Odds of HPV infections among sexually active 27-59 year-old females by
socio-demographic and sexual behavioral characteristics
Characteristics

Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Other

HRa oncogenic types HPV
South
Otherc
d
aOR
aORd

Any oncogenicb types HPV
South
Otherc
d
aOR
aORd

Ref.
0.72 (0.321.7)
0.57 (0.241.3)

Ref.
0.63 (0.251.6)
0.76 (0.311.8)

Ref.
0.88 (0.362.1)
0.71 (0.391.29)

Ref.
0.52 (0.221.2)
0.78 (0.361.7)

Ref.
5.14 (1.715.2)**
2.98 (0.989.1)

Ref.
2.38 (1.234.6)**
4.26 (1.3713.3)*

Ref.
4.27 (1.4412.6)**
2.09 (0.697.5)

Ref.
2.20 (1.343.61)**
4.16 (1.769.8)**

Ref.
0.57 (0.152.2)
1.12 (0.522.4)

Ref.
0.51 (0.191.4)
0.26 (0.100.66)**

Ref.
0.56 (0.152.2)
1.32 (0.503.5)

Ref.
0.58 (0.261.3)
0.34 (0.150.78)*

Marital Status
Married
Never married
Divorced/separated/coh
abitating
Federal poverty level
<100%
100-299%
300-499%
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≥ 500%

0.79 (0.331.9)

0.57 (0.251.28)

0.80 (0.381.7)

0.69 (0.311.5)

Ref.
0.58 (0.271.2)

Ref.
0.92 (0.302.78)

Ref.
0.45 (0.201.02)

Ref.
0.97 (0.322.9)

Ref.
1.92 (0.458.3)

Ref.
1.84 (1.133.0)**

Ref.
1.64 (0.407.1)

Ref.
1.57 (0.922.6)

Ref.
1.32 (0.982.23)

Ref.
3.78 (1.69.0)**

Ref.
1.43 (0.82.53)

Ref.
3.9 (1.98.0)***

Ref.
1.26 (0.53.2)

Ref.
0.87 (0.591.3)

Ref.
.07 (0.422.74)

Ref.
0.47 (0.240.93)*

Health insurance
No
Yes
No. of sex partners 5+
years older
None
≥1
No. of lifetime sex
partners
≤3
≥4
Age at first sexual
intercourse
9-14 years
≥ 15 years

a

HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59

b

HPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 58, and 59

c
d

Northeast, West, and Midwest combined

adjusted odds ratio

*p<0.05; ** p<0.01; *** p<0.001
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Manuscript 2
Impact of Virginia’s HPV Vaccine School-Entry Mandate on HPV
Vaccination among 13 ̶ 17 Year-Old Females
Abstract
The link between human papillomavirus (HPV) and anogenital cancers is well
established in the literature. Many states have passed laws requiring funding for HPV
education or vaccination. Mandatory HPV vaccination policies have been considered and
passed in several states; yet their effectiveness has not been evaluated. This study sought
to assess the impact of Virginia’s HPV vaccine mandate for girls entering sixth grade on
HPV vaccine uptake among adolescent females aged 13 ̶ 17 years.
Data from the National Immunization Survey-Teen for the 2008 ̶ 2012 period
were used, and 3,203 adolescent females were included in the analysis. A difference-indifferences estimation, and logistic regression with a policy-period interaction term were
performed. Virginia was considered the treatment state, and South Carolina and
Tennessee were the comparison states to account for non-policy factors that may have
affected vaccination rates during the time period considered in the analysis.
There was no evidence of an effect of the HPV vaccination policy on vaccination
rates or on physician vaccination recommendation using either the difference-indifferences analysis or the policy-period interaction term in the logistic regression.
Physician recommendation was the factor most strongly associated with vaccination in
the Virginia-South Carolina analysis (aOR=10.3; 95%CI: 6.4-16.6) and in the VirginiaTennessee analysis (aOR=9.33; 95%CI: 6.11 ̶ 14.3).
Study findings suggest that Virginia’s HPV vaccine mandate did not lead to a
significant increase in HPV vaccination among adolescent females or physician
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recommendations. However, physician recommendation was strongly associated with
vaccination.
Background
The link between human papillomavirus (HPV) and oropharyngeal, penile, anal,
vulvar, vaginal, and cervical cancers is well established (Forman et al., 2012). To date,
two HPV preventative vaccines have been licensed by the Food and Drug Administration
(Centers for Disease Control and Prevention, 2010a, 2010b; U.S. Food and Drug
Administration, 2014). The Advisory Committee on Immunization Practices (ACIP)
recommends routine HPV immunization for 11 ̶ 12 year-old adolescents (Centers for
Disease Control and Prevention, 2012). HPV vaccination rates have increased in the
United States, but they remain below Healthy People 2020’s goal of 80% (United States
Department of Health and Human Services, 2014). In 2014, among adolescent females
aged 13 ̶ 17 years, the overall HPV vaccine initiation rates were higher among nonHispanic Blacks (66.4%) and Hispanics (66.3%) as compared to non-Hispanic Whites
(56.1%) (Reagan-Steiner et al., 2015). However, HPV vaccine completion rates were
very low for all ethnic groups, with Hispanics having the highest rates (46.9%) followed
by Blacks (39.0%), Whites (37.5%), and Asians (35.7%) (Reagan-Steiner et al., 2015).
In January 2007, three bills (SB1230, HB2035, SB1914) were introduced in
Virginia to include HPV vaccine among vaccines required for school (Virginia
Legislative Information System, 2007). As originally introduced, SB1230 and HB2035
would require that females received three doses of the HPV vaccine (Virginia Legislative
Information System, 2007). These bills did not include an opt-out option in addition to
the regular exemptions for all other childhood vaccines (Virginia Legislative Information
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System, 2007). The third bill, SB1914, would require females to receive three doses of
the HPV vaccine, but it provided an opt-out option to parents after having read approved
HPV educational materials (Virginia Legislative Information System, 2007).
Before they were enacted, HB2035 and SB1230 incorporated SB 1914 based on
the governor’s recommendation to include an opt-out option to parents since HPV is not
transmissible in a school setting (Virginia Legislative Information System, 2007).
HB2035 and SB1230 are identical and were both effective on October 1, 2008 (Virginia
Legislative Information System, 2007). In the District of Columbia, a bill requiring HPV
vaccination certificate was introduced in January 2007 (Council of the District of
Columbia, 2007). Before the bill was passed, similar to the change in Virginia’s bills, it
included an opt-out option for parents after having read the educational materials
provided (Council of the District of Columbia, 2007).
More than twenty states have passed laws requiring funding for HPV education,
or HPV vaccination while three others distribute free HPV vaccines through their health
departments. Only the District of Columbia, Virginia, and Rhode Island have passed a
HPV vaccine mandate (National Conference of States Legislatures, 2015). Mandatory
school-entry HPV vaccine policy has been considered in several states; yet its impact on
HPV vaccination has not been evaluated. This study assessed the impact of Virginia’s
HPV vaccine mandate for school-entry for girls entering sixth grade on vaccination
among 13 ̶ 17 year-old adolescent females, using data from the National Immunization
Survey-Teen (NIS-Teen).
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Methods
NIS-Teen Survey
The purpose of the National Immunization Survey (NIS) is to estimate
vaccination coverage among children 19 to 35 months old (Curtin, Lester et al., 2013).
The NIS-Teen is a NIS appended survey, which uses random digit dialing telephone
survey of households to provide an estimation of vaccination coverage among
adolescents. NIS-Teen data collection is conducted in two stages: a household telephone
survey that collects information on immunization status of adolescents from the teen’s
parent or guardian, along with a permission request to contact the adolescent’s healthcare
provider; and an immunization questionnaire mailed to teen’s healthcare providers
(Curtin, Lester et al., 2013). For the telephone interview, the adult who is most informed
about the child’s vaccinations is chosen to answer the questions. NIS-Teens’ detailed
survey methodologies have been published elsewhere (Curtin, Lester et al., 2013).
Study Design
The current study used a pre-post design (difference-in-differences) with a
comparison group from a natural experiment. A natural experiment is one in which an
intervention varies through the natural occurrence of an event that is exogenous to the
outcome of interest (Petticrew et al., 2005; Remler & Van Ryzin, 2011). It allows
comparisons between a group that experiences the predetermined event and a group that
did not (Petticrew et al., 2005; Remler & Van Ryzin, 2011). Although several methods
have been used to assess effectiveness of public health policies, difference-in-differences
is among the most widely used methods (Mason et al., 2015; Rajaram et al., 2014).
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Difference-in-differences estimates the treatment effect on the treated group by
subtracting the change in the outcome for the comparison group before and after the
treatment from the change in the outcome for the treatment group before and after the
treatment (Descy & Tessaring, 2004; Meyer, 1995a). Taking the difference of the group
differences allows the control of unobserved differences that may bias the treatment
effect estimate (Descy & Tessaring, 2004; Meyer, 1995a).
Treatment and Comparison States
Virginia is located in the Southern Black Belt, a part of the American South. Its
neighboring states in the Black Belt include North Carolina, Tennessee, and South
Carolina. North Carolina has enacted legislation requiring the Department of Health to
provide HPV-related information to parents with children in grades five through 12 in
2007 (National Conference of States Legislatures, 2015). As a result, North Carolina
could not be a comparison state for Virginia.
In South Carolina, a bill that would require HPV vaccine for girls after their 11th
birthday or before entering the sixth grade was introduced in 2007. The bill was not
enacted (National Conference of States Legislatures, 2015). Another bill that would
require the Department of Health to offer HPV vaccine to girls before entering the
seventh grade was introduced but was vetoed by the governor in June 2012. The House
sustained the veto (National Conference of States Legislatures, 2015). HPV vaccine
opponents expressed their concerns regarding side effects as well as potential increase in
sexual promiscuity. On her side, Governor Haley stated lack of funding as her reason for
vetoing the bill (South Carolina Radio Network, 2014). In Tennessee, mandatory HPV
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vaccine policy was not introduced. A bill that would require the Department of Health to
provide a report of the prevalence of HPV infection by age group accompanied by a HPV
vaccine recommendation was introduced but not enacted (National Conference of States
Legislatures, 2015).
In the Black Belt, Virginia has the lowest poverty rate (10.4%) (U.S. Census
Bureau, 2014b), and highest high school graduation rate among 18 ̶ 24 year-olds (87%)
for the 2007 ̶ 2012 period compared to the other states in that region (U.S. Census
Bureau, 2014a). Virginia is the only state in the region with median household income
greater than the U.S. average. For the 2007 ̶ 2010 period, Virginia’s median household
income was $60,503 (U.S. Census Bureau, 2013a). For the same time period, the median
household income was $42,295 in South Carolina, and $40,025 in Tennessee (U.S.
Census Bureau, 2013a). During the 2007 ̶ 2012 period, South Carolina had 82.3% of
individuals aged 18 ̶ 24 years with a high school diploma, and the poverty rate was 15.7%
(U.S. Census Bureau, 2014a). During the same period, the poverty rate was 16.3%, and
82.3% of individuals aged 18 ̶ 24 years had a high school diploma in Tennessee (U.S.
Census Bureau, 2014a). Both South Carolina and Tennessee were chosen as comparison
states for Virginia for a more robust analysis.
Sample and Population
Virginia’s policy was implemented during the 2009 ̶ 2010 school year (Virginia
Department of Health, 2014). The pre-policy period was 2008 (before), the
implementation year was 2009 (Virginia Department of Health, 2014), and the postpolicy period was 2010 ̶ 2012 (after). The sample for this analysis included 1,064 female
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adolescents aged 13 ̶ 17 years living in Virginia, 1,084 living in South Carolina, and
1,055 from Tennessee whose parent or guardian provided a response to HPV vaccination
questions during the telephone survey.
Variables
Selected adolescent females’ race/ethnicity, age, state of residence, health
insurance status, healthcare visits in the past 12 months, HPV vaccination history,
maternal education level, maternal income, and maternal marital status were included in
the analysis. For the purpose of this study, teens who had received at least one dose of the
HPV vaccine series were classified as vaccinated. Immunization data from healthcare
providers tend to be more accurate than self-reported. However, adolescents with
sufficient immunization information from their healthcare provider are a subset of those
who participated in the telephone interview. The kappa agreement between HPV
vaccination status from the telephone survey and HPV vaccination status from provider
was 92.5%.
Statistical Analysis
Weighted Pearson’s chi-square test to investigate the variation of different
demographic factors between Virginia and its comparison states was performed.
Additionally, we estimated a difference-in-differences model to quantify the difference in
the change in vaccination rates between Virginia and South Carolina, and between
Virginia and Tennessee before and after the policy implementation. Subsequently, a
logistic regression analysis with ‘policy’ and ‘period’ interaction was performed to
estimate the difference-in-differences in HPV vaccination among females living in
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Virginia or its comparison states in order to control for demographic variables using the
following model:
Logit (Pr(Y =1|period, treatment, period*treatment, age…… physician recommendation))
= α + ϒ1*state + ϒ2 *period+ ϒ3 *(period * state) + βX (1)
Y is HPV vaccination (1 = yes/0 = no), and X is a vector of control variables that
included age, medical visits, maternal education, maternal income, and physician
recommendation. Two logistic regression models were built to estimate difference-indifferences in HPV vaccination. The first model included the policy, the period, and the
policy and period interaction variables. For the second model, the demographic variables
were added to the first model. To estimate difference-in-differences in physician
recommendation while controlling for demographic variables, two logistic regression
models were built using the following model:
Logit (Pr(Y =1|period, treatment, period*treatment, age……and maternal income)) = α +
ϒ1*state + ϒ2 *period+ ϒ3 *(period * state) + βX (2)
Y is HPV vaccine recommendation from a physician (1 = yes/0 = no), and X is a
vector of control variables. A linktest was performed to assess the fit of the model. A pvalue <0.05 was used as the threshold for statistical significance. All statistical analyses
were performed using STATA 13 (StataCorp, 2013), and all estimates were weighted to
females aged 13-17 in the relevant states and years included in each analysis.
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Results
HPV Vaccination
Vaccination rates followed similar trends in Virginia and South Carolina from
2008 to 2012 (Figure 1). In the pre-policy year, vaccination rates were 33.9% in Virginia,
20.8% in South Carolina, and 27.0% in Tennessee. In 2009, which is the year of the
implementation of Virginia’s policy, vaccination rates were 37.9% in Virginia, 31.3% in
South Carolina, and 40.7% in Tennessee. For the first year post-policy, vaccination rates
were 47.1%, 39.7%, and 29.7% in Virginia, South Carolina, and Tennessee, respectively.
In 2011, the rates were 42.0% for Virginia, 34.7% in South Carolina, and 36.1% in
Tennessee. The rates were 48.8%, 36.1%, and 51.5% in Virginia, South Carolina, and
Tennessee, respectively, in 2012 (Figure 1). The difference-in-differences in the
vaccinated proportions between Virginia and South Carolina or Virginia and Tennessee
was not significant (Table 1).
[Figure 1 Here]
[Table 1 Here]
For the difference in selected socio-demographic and health utilization
characteristics, in the pre-policy period, the sample of adolescent females in Virginia and
South Carolina differed by vaccination status, race/ethnicity, health insurance coverage
history, and household income (Table 2). For Virginia and Tennessee, adolescents
differed by race and ethnicity, age, health insurance coverage history, and household
income (Table 2). In the post-policy period, the sample of adolescent females in Virginia
and South Carolina differed by vaccination status, race/ethnicity, number of medical
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visits in the previous year, the proportion who had received a HPV vaccine
recommendation, age at last medical visit, the proportion who had their 11–12-year-old
medical check-up, maternal marital status, education, and income (Table 3). For Virginia
and Tennessee, adolescents differed by vaccination status, race/ethnicity, mother’s
marital status, mother’s education level, and income level (Table 3).
[Table 2 Here]
[Table 3 Here]
In the first Virginia-South Carolina logistic regression model, adolescent females
in Virginia had greater odds of being vaccinated compared to those living in South
Carolina (aOR=1.95; 95%CI: 1.23 ̶ 3.07). Females in both states had greater odds of
vaccination in the post- compared to the pre-policy period (aOR=2.22; 95%CI: 1.51 ̶
3.27). The policy and period interaction term was not significant (Table 4). In the second
Virginia-South Carolina model, adolescent females who were recommended the vaccine
had higher odds of being vaccinated (aOR=10.3; 95%CI: 6.4 ̶ 16.6). Also, those who had
four to six medical visits the previous year had higher odds of vaccination compared to
those who had fewer visits (aOR= 2.04; 95%CI: 1.24 ̶ 3.35) (Table 4).
In the first Virginia-Tennessee model, females were more likely to be vaccinated
in the post- compared to the pre-policy period (aOR= 1.71; 95%CI: 1.19-2.44). The
policy variable and the interaction term were not significant (Table 4). In the second
Virginia-Tennessee model, females had higher odds of being vaccinated in the postcompared to the pre-policy period (aOR= 2.26; 95%CI: 1.02-5.00). Females who were
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recommended the vaccine had higher odds of being vaccinated (aOR=9.33; 95%CI: 6.11 ̶
14.3) (Table 4).
[Table 4 Here]
Physician Recommendation
Physician recommendation rates followed similar trends in Virginia and South
Carolina from 2008 to 2012 (Figure 2). In 2008, the pre-policy year, vaccine
recommendation rates were 46.7% in Virginia, 41.2% in South Carolina, and 40.9% in
Tennessee. In 2009, the year of the implementation of Virginia’s policy, vaccine
recommendation rates were 52.6% in Virginia, 41.6% in South Carolina, and 48.5% in
Tennessee. For the first post-policy year, vaccine recommendation rates were 51.2%,
44.7%, and 49.5% in Virginia, South Carolina, and Tennessee, respectively. In 2011, the
rates were 55.6% in Virginia, 48.0% in South Carolina, and 49.1% in Tennessee. The
rates were 65.4%, 50.8%, and 66.5% in Virginia, South Carolina, and Tennessee,
respectively, in 2012 (Figure 2).
[Figure 2 Here]
The difference-in-differences in the percentage of female adolescents who
received physician recommendation for HPV vaccine between Virginia and South
Carolina and between Virginia and Tennessee was not significant (Table 5). For the first
Virginia-South Carolina logistic regression model predicting the odds for physician
recommendation, none of the variables was significant. For the second model, females
who had seven to nine medical visits had higher odds to receive a physician
recommendation for HPV vaccine compared to those who had fewer visits (aOR= 2.36;
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95%CI: 1.09 ̶ 5.11). Those whose family income was unknown had lower odds of
receiving a HPV vaccine recommendation (aOR=0.33; 95%CI: 0.14 ̶ 0.76). Female
adolescents who were continually insured since age 11 had lower odds of receiving a
HPV vaccine recommendation (aOR=0.33; 95%CI: 0.17 ̶ 0.66) (Table 6).
In the first Virginia-Tennessee model, the odds of HPV vaccine recommendation
were higher in the post- compared to the pre-policy period (aOR=1.77; 95%CI: 1.28 ̶
2.45). The remaining variables were not significant (Table 6). In the second model,
females whose mother graduated high school (aOR=2.24; 95%CI: 1.09 ̶ 4.6), had some
college education (aOR=3.14; 95%CI: 1.49 ̶ 6.59), or graduated college (aOR=2.87;
95%CI: 1.34 ̶ 6.1) had higher odds of receiving a physician recommendation for the
vaccine compared to those whose mother did not graduate from high school.
Additionally, females living in household with income level above poverty and ≤$75,000
had lower odds of receiving a HPV vaccine recommendation compared to those in
households of more than $75,000 (Table 6).
[Table 5 Here]
[Table 6 Here]
Discussion
There was no evidence of improvement in vaccination rates associated with the
mandatory school-entry vaccination policy in either the Virginia-Tennessee or the
Virginia-South Carolina comparisons. Results were similar in both the difference-indifferences analysis and the logistic regression. Moreover, after we controlled for
demographic factors, females in Virginia did not have higher odds of being vaccinated
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compared to those either in South Carolina or Tennessee. Those who had more than three
medical visits in the previous year had higher odds of being vaccinated. Females from all
three states had higher odds of vaccination in the post- compared to the pre-policy period.
HPV vaccine recommendation was consistently associated with HPV vaccination. This
association is in agreement with the literature (Mazza, Petrovic, & Chakraborty, 2012;
Perkins et al., 2013; Reiter, McRee, et al., 2013; Vadaparampil et al., 2011). However,
there was also no evidence that the mandatory vaccination for school-entry increased
physician recommendations for the vaccine.
There are several reasons why Virginia’s HPV vaccine school-entry mandate may
not have resulted in a significant increase in HPV vaccination. First, parents or guardians
of females entering sixth grade were not required to provide proof of HPV immunization
like they do for other required vaccines (Virginia Department of Health, 2014). Second,
after reading the HPV educational materials, parents who opposed HPV vaccination for
their daughters could opt-out without having to provide any documentation for their
refusal. Additionally, parents in Virginia have not only expressed concerns regarding the
safety of the vaccine (Liddon, Hood, & Leichliter, 2012), but also about the possibility
that adolescents will interpret their receipt of the vaccine as a license to be sexually active
or to practice risky sexual behaviors (Scarinci, Garcés-Palacio, & Partridge, 2007;
Schuler, Reiter, Smith, Brewer, & Hill, 2011). Moreover, negative opinions regarding the
HPV vaccine mandate were common in the media (Casciotti et al., 2014), and several
parental rights groups viewed the mandate as an infringement on parental rights despite
the loose opt-out option (Casciotti et al., 2014; Natural News Network, 2015; PR
Newswire, 2015). Reasons cited for mandate opposition included government distrust,
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sexual transmission concern, and infringement of parental autonomy (Casciotti et al.,
2014). Furthermore, since the passing of the mandate, the legislature has introduced
several bills to repeal it (National Conference of States Legislatures, 2015). Evidently,
Virginia’s socio-political environment did not facilitate the effectiveness of the mandate.
Strengths and Limitations
Although this study is among the firsts to assess the impact of Virginia’s mandate
on HPV vaccination, it is not without limitations. One major limitation of the research is
the use of pooled cross-sectional data. Moreover, the policy and the control states have
some similarities but are not exactly identical. Difference-in-differences assumes that
time-varying unmeasured characteristics are constant over the time period in the policy
state and do not correlate with HPV vaccinations. Although we verified that any
significant change did not take place for some of the unmeasured characteristics in the
dataset such as bills directly impacting Medicaid expansion under the Affordable Care
Act and Medicaid and CHIP eligibility. This assumption could not be fully tested.
Despite the aforementioned limitations, the present study used data from a
nationally representative sample that is robust against selection bias. Additionally, this
study is among the first few to assess the impact of Virginia’s HPV vaccine mandate for
school-entry on vaccine uptake among female adolescents while similar policies are
being considered in several states. Moreover, the initial sample size decreased for the
logistic regression models due to missing observations, but the power did not fall below
80%. Furthermore, a general pitfall in policy analysis is “policy endogeneity,” which
would occur, in this case, if Virginia’s HPV vaccine school-entry mandate were adopted
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to increase HPV vaccination, because of low HPV vaccination in Virginia. There was no
indication that Virginia adopted the policy mandate due to low HPV vaccination. Prior to
the passing of the mandate, Virginia’s HPV vaccination rates were higher than those of
the neighboring states. Therefore, there is no evidence of “policy endogeneity”.
Implications for Practice
The current study assessed an important policy that may have served as a model
for other states with high cervical cancer rates. Results revealed that the HPV vaccine
mandate for school-entry did not yield the intended results. However, these results do not
suggest that HPV vaccine mandates cannot be successful. The socio-political
environment in which the mandate was passed is an important factor that may influence
its impact. In Virginia, the socio-political context was not favorable to the mandate. Most
parents had a positive perception of physician recommendation even if they chose not to
vaccinate their adolescents (Perkins et al., 2014). Therefore, it is necessary for policymakers to understand that physician recommendation must accompany the mandate in
order for it to yield the desired results. Since the introduction of HPV vaccine, the
prevalence of HPV infection has decreased by more than 50% among 14-19 year-old
females in the United States (Markowitz et al., 2013), despite low HPV vaccination rates.
We must continue to educate parents about the vaccine’s effectiveness at reducing HPV
infection from the types covered by the vaccine and the implications of this decline in
order to facilitate physician recommendation.
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Conclusion
Study findings did not indicate that Virginia’s HPV vaccine mandate led to a
significant increase in HPV vaccination among adolescent females. Despite Virginia’s
mandate, physician recommendation remains the consistent predictor of HPV
vaccination. While the mandate may be viewed as infringement of parental rights by
some, a physician recommendation is not viewed as such. As a result, efforts to
encourage physician recommendation must continue along with research to better
understand the facilitators of physician recommendation.
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Figure 1. HPV vaccinationⱡ trends in Virginia, South Carolina, and Tennessee, 20082012
HPV Vaccination Trends in Virginia, South Carolina, &
Tennessee, 2008-2012
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*Policy implementation year
ⱡ ≥1 dose of HPV vaccine

Table 1. Difference-in-differences in HPV vaccinationⱡ rates, Virginia and South
Carolina, and Virginia and Tennessee

N=2,119

Pre-policy Period Post-policy period Difference
(2008)
(2010-12)
Virginia
0.339
0.460
0.121
South Carolina
0.208
0.368
0.160
Difference-in-differences
-0.039
N= 2,139
Virginia
0.339
0.460
0.121
Tennessee
0.27
0.387
0.117
Difference-in-differences
0.004
* p <0.05
ⱡ ≥1 dose of HPV vaccine
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Table 2. Difference in selected demographic characteristics in Virginia and South
Carolina, and Virginia and Tennessee pre-policy period

Characteristics

Vaccinated
No
Yes
Race and ethnicity
Hispanic
White
Black
Other
Teen's age
13-15years
16-17 years
No. of medical
visits last year
1 to 3
4 to 6
7 to 9
Ever been insured
since age 11?
yes
No
HPV vaccine
recommendation
No
Yes

Pre-policy period (2008)
pS. Carolina
Tennessee
value
(n=295)
(n=239)
%(95% CI)
%(95% CI)
0.004
66.2 (59.0- 79.2 (73.0-84.3)
73.0 (66.572.6)
78.6)
33.8 (27-41) 20.8(15.8-27.0)
27.0 (21.333.5)
0.04
6.9 (4.2-11.3)
4.7 (2.4-8.5)
3.2 (1.5-6.9)
64.7 (57.255.4(48.7-61.8)
70.9 (63.671.6)
77.3)
24.4 (18.0- 36.8 (30.5-43.7)
22.3 (16.332.2)
29.8)
3.9 (2.2-6.7)
3.2(1.8-5.7)
3.6 (1.9-6.5)
0.47
64.7 (57.661.3(54.8-67.4)
55.0 (48.371.3)
61.6)
35.3 (28.738.7(32.6-45.2)
45.0 (38.442.4)
51.7)
0.57
Virginia
(n=298)
%(95% CI)

72.8 (66.178.6)
22.7(17.329.1)
4.6(2.4-8.5)

77.1(70.8-82.4)
19.6 (14.7-25.7)
3.3 (1.5-6.9)

9.4(6.1-14.2)
90.6(85.8-93.9)

58.8 (52.0-65.3)
41.2(34.7-48.0)
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0.042

0.048

0.36

0.009
12.2 (7.8-18.6)
87.8 (81.492.2)

0.27
53.3(45.960.5)
46.7 (39.554.1)

0.14

75.5(69.380.8)
17.9(13.223.9)
6.6(4.3-9.9)
0.049

4.0 (1.8-8.5)
96.0 (91.598.2)

pvalue

0.24
59.1(52.365.5)
40.9(34.547.7)

Age at last medical
visits
less than 11 years
11 years or older
Teen had an 11-12year-old check-up?
No
Yes
Marital status of
mother
Married
Not married
Mother's education
level
Less than high
school
High school
Some College
college graduate

0.63
4.9(2.4-9.6)
95.1(90.497.6)

6.0 (3.7-9.6)
94.0 (90.4-96.4)

0.94

9.6(6.1-14.7)
90.4 (85-393.9)

0.53

0.09
7.6(4.0-13.7)
92.4 (86.396.0)

13.7 (9.5-19.3)
86.3 (80.7-90.5)
0.49

54.2 (38.069.6)
45.8 (30.443.6)

61.2 (49.2-72.1)

0.23
67.3(51.779.8)
32.7 (20.248.3)

88.8 (27.9-50.8)
0.13

0.33

9.5(6.0-14.8)

11.5(8.1-16.2)

12.8(8.6-18.6)

27.4 (21.134.8)
25.7 (20.032.3)
37.4 (31.044.3)

31.6(25.4-38.5)

32.9 (26.640.0)
24.0 (18.929.8)
30.3 (25.436.2)

30.6(25.1-36.8)
26.2(21.4-31.7)

Household income
Above poverty
>$75,000
Above poverty
<= $75,000
Below poverty
level
Unknown

4.7(2.7-8.2)
95.3(91.897.3)

0.005

0.001
4

47.0 (40.054.2)
42.6 (35.549.9)
7.2(4.3-11.8)

29.7(24.3-35.7)
48.5(42.054.98)
16.6(12.1-22.2)

29.4 (24.235.2)
51.2 (44.657.8)
14.0 (9.5-20.2)

3.2 (1.5-6.6)

5.2(3.2-8.5)

5.4 (3.2-8.9)
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Table 3. Difference in selected demographic characteristics in Virginia and South
Carolina, and Virginia and Tennessee post-policy period
Characteristics

Virginia
(n=766)
%(95% CI)

Vaccinated
No
Yes

54.0 (49.658.5)
46.0 (41.550.4)

Race and ethnicity
Hispanic
White
Black
Other
Teen's age
13-15years
16-17 years

8.6 (6.211.8)
59.7 (55.264.0)
24.1 (20.128.7)
7.6 (5.9-9.6)

Post-policy period (2010-12)
pS. Carolina
Tennessee
value
(n=789)
(n=816)
%(95% CI)
%(95% CI)
0.004
63.2 (58.7-67.4)
61.3 (56.965.5)
36.8 (32.6-41.3)
38.7 (34.543.1)
7E04
4.4(3.0-6.4)
4.5 (3.0-6.5)
56.6 (52.0-61.0)
34.0 (29.6-38.7)
5.0 (3.3-7.6)
63.8 (59.0-67.9)

0.7

0.16

0.026

1 to 3
4 to 6
7 to 9
Ever been insured
since age 11?
yes
No

79.8 (76.282.9)
16.6 (13.719.9)
3.7 (2.4-5.6)

73.2 (69.0-77.0)
20.5 (17.0-24.4)
6.3 (4.5-8.8)

0.74

11.6 (8.2-16.2)

7.9 (5.2-11.6)

88.4 (83.8-91.8)

92.1 (89.494.8)

HPV vaccine
recommendation
No

78.0 (74.381.3)
15.8 (13.019.2)
6.1 (4.4-8.4)
0.09

7.1 (4.511.0)
92.9 (89.095.5)

0.46

0.003
42.6 (38.347.0)

52.2 (47.7-56.6)
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0.003

60.2 (60.064.3)
39.8 (35.744.0)

36.2(32.1-40.5)

No. of medical
visits last year

0.023

70.2 (65.974.3)
20.3 (16.624.6)
5.0 (3.4-7.2)
0.41

61.4 (57.265.4)
38.6 (34.642.8)

pvalue

44.9 (40.649.3)

Yes
Age at last medical
visits
less than 11 years
11 years or older

57.4
(53.61.7)

47.8 (43.4-52.3)

2.4 (1.5-3.8)
97.6 (96.298.5)

5.8(3.8-8.6)
94.2 (91.4 96.2)

6.7 (4.7-9.4)

10.8 (8.2-14.3)

Yes

93.3 (90.695.3)

89.2 (85.7-91.8)

Mother's education
level
Less than high
school
High school
Some College
college graduate

0.34
91.7 (89.193.7)
8.3 (6.3-10.9)

1E05
74.7 (70.478.6)
25.3 (21.429.7)

56.9 (52.3-61.4)

0.001
64.8 (60.469.0)
35.2 (31.0 39.6)

43.1 (38.6-47.7)
1E05

7.6 (5.510.3)
23.4 (19.627.7)
23.6 (20.127.5)
45.4 (41.349.7)

0.002

11.1(8.4-14.6)

9.9 (7.6-12.9)

30.0 (25.9-34.5)

29.9 (26.034.0)
26.8 (23.130.8)
33.4 (29.737.5)

29.8(25.9-33.9)
29.1 (25.7-32.7)

Household income
Above poverty
>$75,000
Above poverty
<= $75,000
Below poverty
level
Unknown

3.9 (2.5-6.1)
96.1 (93.997.5)
0.032

No

Not married

0.14

0.004

Teen had an 11-12
year-old check up?

Marital status of
mother
Married

55.1 (50.759.4)

1E05
44.0 (39.948.1)
35.9 (31.840.1)
13.6 (10.417.6)
6.6 (4.7-9.1)

25.0 (22.0-28.3)
39.7 (35.5-44.0)
30.0 (25.7-34.7)
5.3 (3.8-7.3)
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1E05
27.1 (23.830.6)
43.5 (39.347.8)
23.7 (19.928.0)
5.8 (4.1-8.0)

Table 4. Odds ratios for HPV vaccination according to selected characteristics,
Virginia, South Carolina, and Tennessee
Characteristic
s
Policy
implemented
No
Yes

Virginia & S. Carolina
Model 2
Model 2
(n=2,119)
(n= 957)
aOR (95%CI)
aOR (95%CI)

Virginia and Tennessee
Model 1
Model 2
(n=2,119)
(n=976)
aOR (95%CI)
aOR (95%CI)

Ref.
1.95 (1.233.07)**

Ref.
3.37 (0.8114.0)

Ref.
1.38 (0.902.13)

Ref.
3.32 (0.94-11.7)

Ref.
2.22(1.513.27)***

Ref.
2.72 (0.99 7.47)

Ref.
1.71 (1.192.44**)

Ref.
2.26 (1.02-5.0)*

0.75 (0.441.26)

0.52 (0.122.23)

0.97 (0.601.61)

0.56 (0.15-2.12)

Period
Pre
Post
Interaction
term
Policy*perio
d
vaccine
recommendat
ion
No
Yes
Race/
ethnicity
White
Hispanic
Black
Other
Maternal
education
Less than
high school
High school
Some
College
college
graduate

Ref.
10.3 (6.416.6)***

Ref.
9.33 (6.1114.27)***

Ref.
0.77 (0.361.61)
1.34 (0.782.34)
1.57 (0.713.49)

Ref.
0.77 (0.35-1.69)

Ref.

Ref.

1.21 (0.483.07)
0.76 (0.291.97)
0.66(0.261.71)

1.84 (0.83-4.9)

60

0.74 (0.42-1.29)
0.97 (0.43-2.20)

1.13 (0.51-2.52)
1.00 (0.46-2.20)

Household
income
Above
poverty
>$75,000
Above
poverty
<= $75,000
Below
poverty
Unknown
No. of
medical visits
last year
1 to 3
4 to 6
7 to 9
Ever been
uninsured
since age 11
yes
No
Mother's
marital status
Married
Not married
Teen's age
13-15 years
16-17 years
Had 11-12year-old
check-up?
Yes
No

Ref.

Ref.

0.93 (0.581.49)

0.85 (0.53-1.36)

1.13 (0.532.44)
1.05 (0.372.95)

1.38 (0.67-2.87)

Ref.
2.04 (1.243.35)**
1.65 (0.733.72)

Ref.
1.63 (1.03-2.58)*

0.93 (0.36-2.38)

2.52 (1.04-6.11)*

Ref.
0.65 (0.321.31)

Ref.
0.646 (0.31-1.36)

Ref.
0.96 (0.541.71)

Ref.
1.57 (0.92-2.70)

Ref.
1.07 (0.711.62)

Ref.
1.21 (0.812-1.79)

Ref.
1.11 (0.602.07)

Ref.
0.71 (0.36-1.39)
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Figure 2. Physician recommendation trends in Virginia, South Carolina, and
Tennessee, 2008-2012
Physician Recommendation Trends in Virginia, South Carolina, and
Tennessee, 2008-2012
70.0%
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
2008

2009*
Virginia

2010
Tennessee

2011

2012

South Carolina

*Policy implementation year

Table 5. Difference-in-differences in HPV vaccine recommendation rates for
Virginia and South Carolina, and Virginia and Tennessee
Pre-policy Period Post-policy period Difference
(2008)
(2010-12)
Virginia
0.467
0.574
0.107
South Carolina
0.412
0.478
0.066
Difference-in-differences
0.041
N= 2196
Virginia
0.467
0.574
0.107
Tennessee
0.409
0.551
0.142
Difference-in-differences
0.035
* p<0.05; ** p<0.01; *** p<0.001
N= 2163
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Table 6. Odds ratios for physician recommendation according to selected
characteristics, Virginia and South Carolina, and Virginia and Tennessee

Characteristic
s

Policy
implemented
No
Yes

Virginia and South
Carolina
Model 1
Model 2
(N=2,163)
(N= 1000)
aOR (95%CI)
aOR
(95%CI)

Virginia and Tennessee
Model 1
(N=2196)
aOR (95%CI)

Model 2
(N= 1031)
aOR (95%CI)

Ref.
1.25 (0.841.87)

Ref.
1.43 (0.434.71)

Ref.
1.27 (0.85-1.89)

Ref.
0.94 (0.32-2.78)

Ref.
1.31 (0.941.81)

Ref.
1.48 (0.703.14)

Ref.
1.77(1.282.45)**

Ref.
1.18 (0.58-2.37)

1.17 (0.731.89)

0.78 (0.232.67)

0.87 (0.54-1.39)

1.07 (0.34-3.38)

Period
Pre
Post
Interaction
term
Policy*period
Race and
ethnicity
Non-Hispanic
White
Hispanic
Non-Hispanic
Black
Other
Mother's
education level
Less than high
school
High school
Some College
College
graduate

Ref.

Ref.

0.78 (0.331.85)
0.74 (0.461.21)
0.77 (0.391.54)

1.28 (0.55-2.98)

Ref.

Ref.

1.41 (0.692.93)
1.45 (0.703.0)
1.85 (0.903.83)

2.24 (1.09-4.61)*
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0.79 (0.48-1.29)
0.55 (0.30-1.01)

3.14 (1.496.59)**
2.87 (1.346.10)**

Household
income
Above poverty
>$75,000
Above poverty
<= $75,000
Below poverty
level
Unknown
No. of medical
visits last year
1 to 3
4 to 6
7 to 9
Ever been
uninsured since
age 11?
yes
No
Mother's
marital status
Married
Not married
Teen's age
13-15 years
16-17 years
Teen had an
11-12 year-old
check-up
Yes
No

Ref.

Ref.

0.64 (0.411.01)
0.55 (0.281.08)
0.33 (0.140.76)*

0.49 (0.310.76)**
0.73 (0.38-1.38)

Ref.
1.04 (0.651.65)
2.36 (1.095.11)*

0.60 (0.25-1.45)

Ref.
1.43 (0.91-2.24)
1.79 (0.25-1.45)

Ref.
0.33 (0.170.66)**

Ref.
0.76 (0.40-1.58)

Ref.
0.82(0.501.34)

Ref.
1.14 (0.71-1.85)

Ref.
1.09(0.741.61)

Ref.
1.09 (0.76-1.56)

Ref.
0.62 (0.331.17)

Ref.
0.96 (0.50-1.83)

* p<0.05; ** p<0.01; *** p<0.001
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Manuscript 3
Impact of Louisiana’s HPV Vaccine Awareness Policy on HPV Vaccination among
13 ̶ 17 Year-Old Females
Abstract
The Advisory Committee on Immunization Practices recommends routine human
papillomavirus (HPV) immunization for 11 ̶ 12 year-old adolescents. In 2008, Louisiana
required the school boards to distribute HPV vaccine information to parents or guardian
of students in grades 6 ̶ 12. This manuscript investigates the impact of this policy on HPV
vaccination among 13 ̶ 17 year-old female adolescents using National Immunization
Survey-Teen data 2008 ̶ 2012.
Drawing on the data from the 2008-2012 National Immunization Survey (NISTeen), we compared the difference in proportions of females who have been vaccinated
before and after the policy (n=2,327). Using difference-in-difference estimation, we
explored the change in vaccination rates before and after the policy implementation in
Louisiana compared to Alabama and Mississippi, who did not have such a policy in
place.
The difference-in-differences estimate for HPV vaccination was not significant.
Physician recommendation for HPV vaccine recommendation was strongly associated
with vaccination for females in Louisiana and Alabama (aOR=7.74; 95% CI: 5.22 ̶ 11.5)
and for those in Louisiana and Mississippi (aOR=7.05; 95% CI: 4.6 ̶ 10.5). Compared to
the proportion of female adolescents who had received a physician recommendation in
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Alabama or Mississippi, the proportion in Louisiana did not increase significantly in the
post-policy period.
HPV vaccination rates did not increase significantly in Louisiana compared to
Alabama or Mississippi following the implementation of the policy. Despite Louisiana’s
policy, physician recommendation remains the factor most strongly associated with HPV
vaccination. HPV vaccine awareness did not necessarily result in HPV vaccination.
Background
The Food and Drug Administration has licensed two HPV preventative vaccines
since 2014 (U.S. Food and Drug Administration, 2014). The Advisory Committee on
Immunization Practices (ACIP) recommends routine HPV immunization for 11 ̶ 12 yearolds (Centers for Disease Control and Prevention, 2012). HPV vaccination rates remain
well below the 80% coverage of Healthy People 2020 (U.S. Department of Health and
Human Services, 2014). In 2014, only 60% of females aged 13 ̶ 17 years had initiated,
and 39.7% of females had completed the HPV vaccine series (Reagan-Steiner et al.,
2015). Among the males in the same age-group, while 41.7% had initiated, only 21.6%
had completed the vaccine series (Reagan-Steiner et al., 2015).
In March 2008, House Bill 359 (HB359) was introduced to Louisiana’s House of
Representatives. In June 2008, it became Act 210 without the governor’s signature
(Louisiana State Legislature, 2008). Act 210 requires the Department of Health and
Hospitals to provide HPV/HPV vaccine information to the Department of Education,
which would provide this information to the city, parish, and school boards. School
boards are required to distribute the information to parents or guardian of students in
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grades 6 ̶ 12. The HPV/HPV vaccine information must include a form requesting parental
permission to provide HPV information to students directly (Louisiana State Legislature,
2008). When it was first introduced, Louisiana’s HB359 would apply to female students
in sixth grade, but it later included students of both genders in grades six through twelve
(Louisiana State Legislature, 2008).
Several states have passed bills requiring HPV-related education and HPV
vaccine availability for adolescents, or parents, or both. Indiana, Utah, Iowa, New Jersey,
and Washington took the lead on HPV and HPV vaccine awareness legislatures in the
2006 ̶ 2007 period (National Conference of States Legislatures, 2015). Since 2008,
several states have considered HPV vaccine awareness policies, including Kentucky and
Missouri. While several states have implemented policies aimed at increasing HPV
vaccine awareness, the effectiveness of these policies at increasing HPV vaccination has
not been evaluated. This study investigates the impact of Louisiana’s HPV and HPV
vaccine awareness policy on HPV vaccination among 13 ̶ 17 year-old females using
National Immunization Survey-Teen (NIS-Teen) data 2008 ̶ 2012.
Methods
NIS-Teen Survey
The purpose of the National Immunization Survey (NIS) is to estimate
vaccination coverage among children 19 to 35 months old. The NIS-Teen is a NIS
appended survey, which uses random digit dialing telephone survey of households to
provide an estimation of vaccination coverage among adolescents (Curtin, Lester et al.,
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2013). NIS-Teen data collection is conducted in two stages: a household telephone
survey that collects information on immunization status of adolescents from the teen’s
parent or guardian, along with a permission request to contact the adolescent’s healthcare
provider; and an immunization questionnaire mailed to teen’s healthcare providers
(Curtin, Lester et al., 2013). NIS-Teens’ detailed survey methodology has been published
elsewhere (National Centers for Health Statistics, 2013).
Study Design
The current study analyzed the effects of a natural experiment (i.e.
implementation of a HPV vaccination law in Louisiana) using a pre-post implementation
design (difference-in-differences), with the state of Alabama and Mississippi as
comparison groups. A natural experiment is one in which an intervention varies through
the natural occurrence of an event that is exogenous to the outcome of interest (Petticrew
et al., 2005; Remler & Van Ryzin, 2011). It allows comparisons between the group that
experiences the event and the group that did not (Petticrew et al., 2005; Remler & Van
Ryzin, 2011). The different HPV vaccine policies implemented in the southern Black
Belt states are an excellent source of natural variation.
Although several methods have been used to assess the effectiveness of public
health policies, difference-in-differences is among the most widely used methods (Mason
et al., 2015; Patel et al., 2014; Rajaram et al., 2014). Difference-in-Differences estimates
the treatment effect on the treated group by subtracting the change in the outcome for the
comparison group before and after the treatment from the change in the outcome for the
treatment group before and after the treatment (Descy & Tessaring, 2004; Meyer, 1995b).
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This approach controls for unobserved differences that may bias the treatment effect
estimate (Descy & Tessaring, 2004; Meyer, 1995b).
Treatment and Comparison States
Louisiana is located in the Black Belt, which is a part of the South. Other Black
Belt states includes Florida, Georgia, North Carolina, South Carolina, Virginia, Alabama,
Mississippi, Tennessee, Arkansas, and Texas. The Black Belt is known for its high
poverty, high unemployment rates, low educational attainment, high rates of health
disparities, and high concentration of individuals of African descent are characteristic of
this sub-region (Wimberly & Morris, 1997). For this analysis, the control state and the
comparison should be very similar except in HPV policies and other policies that may
influence HPV vaccinations Black Belt states that are in geographic proximity with
Louisiana include Texas, Arkansas, Mississippi and Alabama.
In 2007, Texas enacted a HPV vaccine mandate by executive order, but the
mandate was later overturned by legislature. Additionally, Texas has enacted a bill
requiring the Department of Health to distribute HPV-related educational materials
(National Conference of States Legislatures, 2015). Therefore, Texas could not serve as a
comparison state. In 2010, the Affordable Care Act was signed into law by President
Obama. Initially, it would initially require the expansion of Medicaid, but the Supreme
Court has made the Medicaid expansion an option for states. In the Black Belt region,
only Arkansas implemented the expansion, which increased Medicaid coverage for
children (Rudowitz, Artiga, & Musumeci, 2014). As a result, Arkansas was not chosen as
a comparison state for Louisiana. Neither Alabama nor Mississippi has enacted bills
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requiring the distribution of HPV-related education materials or HPV vaccinations for
girls in the sixth grade.
Louisiana and Alabama are separated by the state of Mississippi. For the 2007 ̶
2010 period, the average median household income was $41,438 in Louisiana, $36,697 in
Mississippi, and $41,911 in Alabama (U.S. Census Bureau, 2013a). During the 2007–
2012 period, the average graduation rate among 18 ̶ 24 year-olds was 79% in Louisiana,
79.4% in Mississippi, and 82.3% in Alabama (U.S. Census Bureau, 2014a). During the
same time period, the average poverty rate was 18.7% in Louisiana, 20.9% in
Mississippi, and 15.7 in Alabama (U.S. Census Bureau, 2014b). Although the high school
graduation rates are more similar between Louisiana and Mississippi, the income and
poverty gap is wider for Louisiana and Mississippi. Due to their similarities with
Louisiana, both states were chosen as comparison states.
Sample and Population
Although Louisiana’s policy became effective in June 2008 (National Conference
of States Legislatures, 2015), the school parishes or boards were responsible for its
implementation (Louisiana State Legislature, 2008). As a result, the implementation did
not occur in the same year all parishes and school boards. The majority of parishes and
school boards did not implement the policy until 2010 (Louisiana Board of Education
representative, Personal Communication, March 7, 2014). The pre-policy period was
2008 ̶ 2009; the implementation year was 2010; and the post-policy period was 2011 ̶
2012. The response rate for the telephone interview was 85.2% for 2008, 85.4% in 2010,
84.7% in 2011, and 75.5% in 2012 (Centers for Disease Control and Prevention &
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National Centers for Health Statistics, 2013). The sample included females aged 13 ̶ 17
years whose parents or guardians responded to questions about HPV vaccination from the
telephone survey. For Louisiana and Alabama 2,630 females and for Louisiana and
Mississippi 2,826 females provided a response.
Variables
Maternal education, maternal marital status, household income, teen’s
race/ethnicity, age, gender, state of residence, health insurance status, healthcare visits in
the past 12 months, and HPV vaccination status were included in the analysis. Teens who
had received at least one dose were classified as vaccinated. HPV vaccination history
from the telephone rather than from the healthcare provider questionnaire were used. The
kappa agreement between HPV vaccination status from the household survey and HPV
vaccination status from provider was 92.5%.
Statistical Analysis
We performed weighted Pearson’s chi-square test to investigate the variation in
demographic factors between Louisiana and Alabama and between Louisiana and
Alabama. Additionally, we estimated a difference-in-differences model to quantify the
difference in the change in vaccination rates between Louisiana and Alabama, and
between Louisiana and Mississippi before and after the policy implementation.
Subsequently, a logistic regression analysis with ‘policy’ and ‘period’ interaction was
performed to estimate the difference-in-differences in HPV vaccination among females
living in Louisiana or Alabama in order to control for demographic variables using the
following model:
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Logit (Pr(Y =1|period, treatment, period*treatment, age…… physician
recommendation)) = α + ϒ1*state + ϒ2 *period+ ϒ3 *(period * state) + βX (1)
Y is HPV vaccination (1 = yes/0 = no), and X is a vector of control variables that
included age, medical visits, maternal education, maternal income, and physician
recommendation. Two logistic regression models were built to estimate difference-indifferences in HPV vaccination while controlling for demographic factors. The first
model included the policy, the period, and the policy and period interaction variables.
For the second model, the demographic variables were added to the first model. To
estimate difference-in-differences in physician recommendation, two logistic regression
models were built using the following model:
Logit (Pr(Y =1|period, treatment, period*treatment, age……and maternal
income)) = α + ϒ1*state + ϒ2 *period+ ϒ3 *(period * state) + βX (2)
Y is HPV vaccine recommendation from a physician (1 = yes/0 = no), and X is a
vector of control variables. A linktest was performed to assess the fit of the model. A pvalue <0.05 was used as the threshold for statistical significance. All statistical analyses
were performed using STATA 13 (StataCorp, 2013), and all estimates were weighted to
females aged 13-17 in the relevant states and years included in each analysis.
Results
HPV Vaccination
In 2008, 28.8% of adolescent females in Louisiana, 25.7% in Alabama, and
18.5% in Mississippi received at least one dose of the HPV vaccine. Vaccination rate
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increased to 36.7% in Louisiana, 37.7% in Alabama, and 20.1% in Mississippi in 2009.
In 2010, vaccination rates increased to 39.9% in Louisiana, remained constant in
Alabama (37.7%), and increased to 23.2% in Mississippi. Vaccination rates increased to
50.4% in Louisiana, 42.2% in Alabama, and 26.5% in Mississippi in 2011. In 2012,
vaccination rates increased to 53.6% in Louisiana, 42.7% in Alabama, and 38.9% in
Mississippi. While the largest increase in vaccination rates in Louisiana was from 2010
to 2011 (39.9 ̶ 50.4%), Alabama’s largest increase was from 2008 to 2009 (25.7 ̶ 37.7%).
For Mississippi, the greatest increase in vaccination was from 2011 to 2012 (26.5 ̶ 38.9%)
(Figure 1).
[Figure 1 Here]
The difference-in-differences in vaccination rates between Louisiana and
Alabama and between Louisiana and Mississippi was not significant (Table 1). In the prepolicy period, females in Louisiana and Alabama differed by insurance coverage history
and household income (Table 2), whereas females in Louisiana and Mississippi differed
by vaccination status, insurance coverage history, vaccine recommendation status, age at
last medical check-up, and 11-12-year-old medical check-up status (Table 2). In the postpolicy period, females in Louisiana and Alabama differed only in vaccination status
while females in Louisiana and Mississippi differed by vaccination status, race/ethnicity,
number of medical visits, history of insurance coverage, vaccine recommendation status,
age at last medical visits, and 11−12-year-old medical check-up status (Table 3).
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[Table 1 Here]
[Tables 2 & 3 Here]

For the logistic regression model fitting, the linktest results were not significant
for any of the models, which indicated that our models ware properly specified. For
females in Louisiana and Alabama, the first logistic regression model indicated that in the
post-policy period, female adolescents had higher odds of taking the vaccine than in the
pre-policy period (aOR=1.60; 95%CI: 1.16 ̶ 2.6). The period and the interaction variables
were not significant (Table 4). In the second model, HPV vaccine recommendation was
strongly associated with vaccination (aOR=7.74; 95%CI: 5.22 ̶ 11.5). Black adolescent
females had lower odds of being vaccinated compared to whites (aOR= 0.58, 95%CI:
0.37 ̶ 0.90). Those with family income below the federal poverty level had higher odds of
being vaccinated (aOR= 2.44; 95%CI: 1.25 ̶ 4.75) compared to those with a family
income of $75,000 or above. Additionally, teens who had seven or more medical visits
had higher odds of vaccination (aOR=2.84; 95%CI: 1.32 ̶ 2.85) compared to those who
had three or fewer visits (Table 4). For Louisiana and Mississippi, the first model
indicates that females in Louisiana had higher odds of vaccination compared to those in
Alabama (aOR=2.01; 95%CI: 1.47-2.8) and females from both states had higher odds of
vaccination in the post-policy period (aOR=2.0 95%CI: 1.4-2.77), but the interaction
term was not significant (Table 4). In the second model, HPV vaccine recommendation
was the only factor associated with vaccination (aOR=7.05; 95%CI: 4.6 ̶ 10.7) (Table 4).
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[Table 4 Here]
Physician Recommendation
In 2008, 38.7% of adolescent females in Louisiana received a HPV vaccine
recommendation from their healthcare provider compared to 42.5% in Alabama, and
28.5% in Mississippi (Figure 2). HPV vaccine recommendation increased to 55.8% in
Louisiana, 50.0% in Alabama, and 34.5% in Mississippi in 2009. Vaccine
recommendation decreased in all three states in 2010. The rates dropped to 44.6% in
Louisiana, 49.5% in Alabama, and 29.7% in Mississippi. In 2011, vaccine
recommendation increased to 51.9% in Louisiana, 57.1% in Alabama, and 40.8% in
Mississippi. It increased to 59.5% in Louisiana, decreased to 53.1% in Alabama, and
increased to 40.8% in Mississippi in 2012. The difference-in-differences in vaccine
recommendation was not significant in the Louisiana-Alabama comparison or in the
Louisiana-Mississippi comparison (Table 5).
[Figure 1 Here]
[Table 5 Here]

For the logistic regression model fitting, the linktest was not significant for any
the models, which indicated that our models are properly specified. For Louisiana and
Alabama, the first logistic regression model estimating the difference-in-differences in
physician recommendation, the odds of receiving a physician recommendation were
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higher in the post- compared to the pre-policy period (aOR= 1.44; 95% CI: 1.06 ̶ 1.95)
(Table 6). The policy and the interaction variables were not significant. In the second
model, females whose mother had some college education (aOR= 1.95; 95%CI: 1.05 ̶
3.60) and were college graduates (aOR= 2.80; 95% CI: 1.47 ̶ 5.35) had higher odds of
receiving HPV vaccine recommendation. Also, adolescent females who had seven or
more medical visits had lower odds of receiving physician recommendation (aOR= 0.40;
95%CI: 0.21 ̶ 0.78). Also, those who did not have their 11 ̶ 12-year-old medical check-up
had lower odds of receiving vaccine recommendation (aOR= 0.52; 95% CI: 0.30 ̶ 0.90)
(Table 6).
For Louisiana and Mississippi, the first logistic regression showed that females in
Louisiana had higher odds of receiving a physician recommendation for the vaccine
(aOR= 1.93; 95% CI: 1.45 ̶ 2.56) (Table 6). Females had higher odds of receiving
physician recommendation in the post- compared to the pre-policy period (aOR= 1.80;
95% CI: 1.035 ̶ 2.42). The interaction term was not significant. In the second model,
females in Louisiana had higher odds of receiving the recommendation compared to
those in Mississippi (aOR= 1.81; 95% CI: 1.05 ̶ 3.1). The interaction term was not
significant. Females whose mother had some college education (aOR= 2.1; 95%CI: 1.07 ̶
4.1) had higher odds of receiving HPV vaccine recommendation. Those who did not have
their 11 ̶ 12-year-old medical check-up had lower odds of receiving a HPV vaccine
recommendation (aOR= 0.48; 95% CI: 0.28 ̶ 0.82) (Table 6).

[Table 6 Here]
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Discussion
HPV Vaccination
The difference-in-differences in HPV vaccination rates between Louisiana and
both comparison states was not significant, suggesting that factors other than Louisiana’s
policy contributed to the increase in vaccination rates observed in Louisiana. The policy
and period interaction term was not significant in the logistic regression models, which
indicated that Louisiana’s policy did not result in a significant increase in vaccination.
In agreement with previous studies, we found physician recommendation to be a
major determinant of HPV vaccination (Reiter, Katz, & Paskett, 2013; Vadaparampil et
al., 2014). Additionally, in Louisiana and Alabama teens living below the poverty level
had higher odds of being vaccinated, and the odds of vaccination did not differ by health
insurance status since teens were 11 years of age. A previous study has reported similar
vaccination rates among uninsured and insured teens (Pierre-Victor, Mukherjee, Bahelah,
& Madhivanan, 2014), and another study has reported higher vaccination rates among
those living below the federal poverty level (Reagan-Steiner et al., 2015). Moreover, in
Louisiana and Alabama, Black females had lower odds of being vaccinated. This finding
contradicts the recent findings reported by Reagan-Steiner and colleagues (ReaganSteiner et al., 2015), but are in agreement with previous studies (Niccolai, Mehta, &
Hadler, 2011; Stokley, Dorell, & Yankey, 2009). Lack of access to care, especially for
those living in rural areas, may contribute to the lower odds of vaccination among Blacks.
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Vaccine Recommendation
The difference-in-differences in vaccine recommendation rates and vaccination
rates between Louisiana and both comparison states was not significant. These findings
suggest that the implementation of the policy did not lead to an increase in vaccine
recommendation. HPV vaccine awareness was not captured in every survey year and
therefore could not be included in the analysis. Females who did not have their 11–12year old check-up had lower odds of receiving a HPV vaccine recommendation.
Adolescent females whose mother had some college education and beyond had higher
odds of receiving a HPV vaccine recommendation or to recall having received a HPV
vaccine recommendation even though their odds of vaccination were not significantly
greater. The higher odds for physician recommendation may result from physicians
assuming that mothers with a college education would be more knowledgeable about the
vaccine and therefore more likely to respond positively to the recommendation for the
vaccine.
Socio-political Context
Contrary to HPV vaccine mandates, vaccine awareness policies were not
surrounded by controversy (Laugesen et al., 2014) nor receive negative news coverage
(Casciotti et al., 2014). Even when parents and adolescents are aware of HPV vaccine,
structural barriers ̶ including lack of transportation, out-of-pocket cost, parental consent,
safety concerns, and parental sexual promiscuity concerns ̶ may hinder adolescents from
taking the vaccine (Kaplan, 2010). Additionally, vaccine awareness must be followed be
vaccine recommendation in order for decision-making to occur.
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Limitations and Strengths
The present study had several limitations. The major limitation of the research is
the use of pooled cross-sectional data. Furthermore, difference-in-differences assumes
that time-varying unmeasured characteristics are constant over the time periods in the
treatment state and do not correlate with HPV vaccinations. We verified that no
significant changes took place for some characteristics not measured in the dataset such
as bills directly impacting Medicaid SCHIP eligibility, and Medicaid expansion under the
Affordable Care Act. However, the assumption that time-varying unmeasured
characteristics are constant over the time periods could not be tested fully. Additionally,
this study uses pooled cross-sectional rather than longitudinal data. Moreover, while the
policy and the control states are similar, they are not identical.
Despite these limitations, this study evaluated an important policy that could serve
as a model for other states in the Black Belt and had several strengths. First, it used data
from a nationally representative sample of non-institutionalized U.S. population.
Additionally, this study is among the first few to assess the impact of Louisiana’s policy
requiring that schools sent HPV/HPV vaccine information to parents of students in grades
6 ̶ 12 on HPV vaccination among13 ̶ 17 year-old females. Furthermore, a potential pitfall
in policy analysis is “policy endogeneity,” which would occur, if Louisiana’s policy was
adopted to increase HPV vaccination due to low HPV vaccination. There was no
evidence that Louisiana adopted its policy due to low HPV vaccination.
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Conclusion
The policy did not lead to HPV vaccination. Nevertheless, the importance of the
delivery of uniform and accurate HPV vaccine information should not be ignored, as the
information prepares parents and adolescents for the physician recommendation. Despite
HPV vaccine awareness among parents, physician recommendation remains the key
predictor of HPV vaccination.
Since provider recommendation plays a vital role in HPV vaccination, we must
continue policy and educational efforts to not only deliver uniform and accurate HPV
vaccine information in order to prepare parents and adolescents for the vaccine
recommendation but also to facilitate physician recommendation. In private practice
settings, the nurse and the physician assistant interact more with the patient than the
physician. Therefore, they are instrumental in patient education and decision-making.
They are in a position to educate the patients about HPV and the vaccine prior to their
meeting with the physician and assist them in the decision-making following the
physician recommendation. In other settings, healthcare providers should continue to
decrease missed opportunities for HPV vaccination. Previous studies have identified
school-based health centers (SBHCs) as a setting with a great potential to increase HPV
vaccination (Golden et al., 2014; Kaplan, 2010), particularly for adolescents in rural areas
and those who may lack access. SHBCs can boost HPV vaccinations by sending parents
educational materials regarding all recommended vaccines along with immunization
consent forms.

80

References
Casciotti, D. M., Smith, K. C., Andon, L., Vernick, J., Tsui, A., & Klassen, A. C. (2014).
Print news coverage of school-based human papillomavirus vaccine mandates.
Journal of School Health, 84(2), 71–81. doi:10.1111/josh.12126
Centers for Disease Control and Prevention. (2012). Advisory Committee on
Immunization Practices: human papillomavirus vaccine resolution. Retrieved March
13, 2015, from
http://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html
Centers for Disease Control and Prevention, & National Centers for Health Statistics.
(2013). National Immunization Survey-Teen A User’ s Guide for the 2011.
Retrieved from http://www.cdc.gov/nchs/nis/data_files_teen.htm
Curtin, Lester, R., Mohadjer, L. K., Dohrmann, S. M., Kruszan-Moran, D., Mirel, L. B.,
Carroll, M. D., … Johnson, C. L. (2013). National Health and Nutrition Examination
Survey: Sample design, 2007 – 2010. Vital and Health Statistics, 2(160).
Descy, P., & Tessaring, M. (2004). Evaluation and impact of education and training: the
value of learning. Retrieved from
http://www.trainingvillage.gr/etv/projects_Networks/researchlab/
Golden, S. D., Moracco, K. E., Feld, A. L., Turner, K. L., DeFrank, J. T., & Brewer, N.
T. (2014). Process evaluation of an intervention to increase provision of adolescent
vaccines at school health centers. Health Education & Behavior, 41(6), 625–632.
doi:10.1177/1090198114531773
Kaplan, D. W. (2010). Barriers and Potential Solutions to Increasing Immunization Rates
in Adolescents. Journal of Adolescent Health, 46, S24–S33.
doi:10.1016/j.jadohealth.2009.12.004
Laugesen, M. J., Mistry, R., Carameli, K. A., Ribisl, K. M., Needleman, J., & Bastani, R.
(2014). Early policy responses to the human papillomavirus vaccine in the United
States, 2006-2010. The Journal of Adolescent Health, 55(5), 659–64.
doi:10.1016/j.jadohealth.2014.04.015
Louisiana State Legislature. (2008). Lousiana House Bill 359. Retrieved March 1, 2016,
from http://www.legis.la.gov/legis/BillInfo.aspx?s=08RS&b=ACT210&sbi=y
Mason, T., Sutton, M., Whittaker, W., McSweeney, T., Millar, T., Donmall, M., …
Pierce, M. (2015). The impact of paying treatment providers for outcomes:
Difference-in-differences analysis of the “payment by results for drugs recovery”
pilot. Addiction, 110(7), 1120–8. doi:10.1111/add.12920
Meyer, B. D. (1995). Natural and quasi-experiments in economics. Journal of Business &
Economic Statistics, 13(2), 151–61. doi:10.2307/1392369
81

National Centers for Health Statistics. (2013). Datasets for the National Immunization
Survey - Teen. Retrieved November 11, 2013, from
http://www.cdc.gov/nchs/nis/data_files_teen.htm
National Conference of States Legislatures. (2015). HPV Vaccine: State Legislation and
Statutes. Retrieved December 24, 2015, from
http://www.ncsl.org/research/health/hpv-vaccine-state-legislation-and-statutes.aspx
Niccolai, L. M., Mehta, N. R., & Hadler, J. L. (2011). Racial/Ethnic and poverty
disparities in human papillomavirus vaccination completion. American Journal of
Preventive Medicine, 41(4), 428–33. doi:10.1016/j.amepre.2011.06.032
Patel, M. S., Volpp, K. G., Small, D. S., Hill, A. S., Even-Shoshan, O., Rosenbaum, L.,
… Silber, J. H. (2014). Association of the 2011 ACGME Resident Duty Hour
Reforms With Mortality and Readmissions Among Hospitalized Medicare Patients.
JAMA, 312(22), 2364. doi:10.1001/jama.2014.15273
Petticrew, M., Cummins, S., Ferrell, C., Findlay, A., Higgins, C., Hoy, C., … Sparks, L.
(2005). Natural experiments: an underused tool for public health? Public Health,
119(9), 751–7. doi:10.1016/j.puhe.2004.11.008
Pierre-Victor, D., Mukherjee, S., Bahelah, R., & Madhivanan, P. (2014). Human
papillomavirus vaccine uptake among males 11-26 years in United States: Findings
from the national health and nutrition examination survey, 2011-2012. Vaccine,
32(49), 6655–6658. doi:10.1016/j.vaccine.2014.09.044
Rajaram, R., Chung, J. W., Jones, A. T., Cohen, M. E., Dahlke, A. R., Ko, C. Y., …
Bilimoria, K. Y. (2014). Association of the 2011 ACGME resident duty hour reform
with general surgery patient outcomes and with resident examination performance.
JAMA, 312(22), 2374–2384. doi:10.1001/jama.2014.15277
Reagan-Steiner, S., Yankey, D., Jeyarajah, J., Elam-Evans, L. D., Singleton, J. A., Curtis,
C. R., … Stokley, S. (2015). National, Regional, State, and Selected Local Area
Vaccination Coverage among Adolescents Aged 13-17--United States, 2014.
MMWR, 64(29), 784–792. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/26225479
Reiter, P. L., Katz, M. L., & Paskett, E. D. (2013). Correlates of HPV vaccination among
adolescent females from Appalachia and reasons why their parents do not intend to
vaccinate. Vaccine, 31(31), 3121–5. doi:10.1016/j.vaccine.2013.04.068
Remler, D. K., & Van Ryzin, G. G. (2011). Natural and quasi experiments. In Research
methods in practice: Strategies for description and causation (pp. 427–464).
Thousand Oaks: California: Sage.

82

Rudowitz, R., Artiga, S., & Musumeci, M. (2014). The ACA and secent section 1115
medicaid demonstration waivers. Menlo Park, CA. Retrieved from www.kff.org
StataCorp. (2013). Stata Statistical Software: Release 13. College Station, Texas:
StataCorp LP.
Stokley, S., Dorell, C., & Yankey, D. (2009). National, state, and local area vaccination
coverage among adolescents aged 13-17 years- United States, 2008. MMWR, 58(36),
997–1001.
U.S. Census Bureau. (2013). Income. Retrieved April 27, 2015, from
http://www.census.gov/hhes/www/income/
U.S. Census Bureau. (2014a). Educational attainment. Retrieved from
httos://www.census.gov/hhes/socdemo/education/
U.S. Census Bureau. (2014b). Poverty. Retrieved April 27, 2015, from
http://www.census.gov/hhes/www/poverty/
U.S. Department of Health and Human Services. (2014). Healthy People 2020.
Washington, D.C. Retrieved from
http://www.healthypeople.gov/2020/about/default.aspx
U.S. Food and Drug Administration. (2014). Press Announcements - FDA approves
Gardasil 9 for prevention of certain cancers caused by five additional types of HPV.
Retrieved June 18, 2015, from
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm
Vadaparampil, S. T., Malo, T. L., Kahn, J. A., Salmon, D. A., Lee, J.-H., Quinn, G. P., …
Giuliano, A. R. (2014). Physicians’ human papillomavirus vaccine
recommendations, 2009 and 2011. American Journal of Preventive Medicine, 46(1),
80–4. doi:10.1016/j.amepre.2013.07.009
Wimberly, R. C., & Morris, L. V. (1997). The Southern Black Belt: A national
perspective. Lexington, KY: TVA Rural Studies Press.

83

Figure 1. HPV vaccinationⱡ trends in Louisiana, Alabama, and Mississippi 20082012
HPV Vaccination Rates in Louisiana, Alabama, and
Mississippi, 2008-2012
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Table 1. Difference-in-differences in HPV vaccination rates in Louisiana and
Alabama, Louisiana and Mississippi
N= 2,162

Pre-policy Period
(2008-09)
0.325
0.317

Post-policy period
(2011-12)
0.519
0.425

Difference

0.325
0.193

0.519
0.323

0.194**
0.13
0.064

Louisiana
Alabama
DiD
N= 2,275
Louisiana
Mississippi
DiD
* p<0.05; ** p<0.01

DiD= difference-in-differences
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0.194**
0.108
0.086

Table 2. Difference in selected demographic characteristics in Louisiana and
Alabama, and in Louisiana and Mississippi, pre-policy period

Characteristics

Louisiana
(n=552 )
% (95% CI)

Alabama
(n=525 )
% (95% CI)

Vaccinated
No 71.2 (65.276.5)
Yes 28.8 (23.534.8)
Race and ethnicity
Hispanic 2.1 (1.0-4.1)
Non-Hispanic White 52.0 (45.458.5)
Non-Hispanic Black 42.5 (35.949.3)
Other 3.5 (1.8-6.3)
Teen's age
13-15years 63.2 (56.969.0)
16-17 years 36.8 (31.043.2)
No. of medical visits
last year
1 to 3 76.7 (70.981.6)
4 to 6 21.0 (16.226.7)
7 to 9 2.3 (1.2-4.5)
Ever been uninsured
since age 11
Yes 4.3 (2.5-7.4)
No 95.7 (92.697.5)

pvalu
e
0.46

74.3 (68.080.0)
25.7 (20.332.0)

Mississippi
(n=626 )
%(95% CI)

0.01
81.5(75.8-86.1)
18.5 (13.924.1)

0.19
2.6 (1.1-6.0)
61.6 (54.468.4)
33.4 (26.840.7)
2.4 (0.936.0)

0.83
2.5 (1.4-4.5)
48.4 (42.154.8)
45.7 (39.552.3)
3.3 (1.8-6.0)

0.54
60.3(53.366.9)
39.7 (33.146.7)

0.9
62.6 (56.268.6)
37.4 (31.443.8)

0.97
76.0 (69.781.3)
21.8 (16.728.0)
2.2 (0.925.1)

0.11
78.4 (72.583.3)
16.4 (12.221.8)
5.2 (2.9-9.2)

0.00
1
13.0 (8.519.4)
87.0 (80.691.5)

HPV vaccine
recommendation

0.02
2
9.6 (6.2-14.8)
90.4 (85.293.8)

0.47
No 61.3 (54.967.2)

57.9 (51.164.4)
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pvalue

0.01
9
71.5 (65.377.0)

Yes 38.7 (32.845.1)
Age at last
medical visits
less than 11 years 4.9 (2.9-8.1)
11 years or older 95.1 (91.997.1)
Teen had 11-12
year-old medical
check-up?
No 16.1 (11.122.7)
Yes 83.9 (77.388.9)
Marital status of mother
Married 61.1 (48.672.3)
Not married 38.9 (27.751.4)
Mother's education level
Less than high 13.7 (9.5-19.3)
school
High school 39.0 (32.645.8)
Some College 27.7 (22.533.5)
college graduate 19.7 (15.624.5)
Household income
Above poverty
>$75,000
Above poverty
<= $75,000
Below poverty level

25.3 (20.530.8)
45.1 (38.851.6)
25.0 (19.032.0)
Unknown 4.6 (2.8-7.3)

42.1 (35.648.9)

28.5 (23.034.7)
0.71

4.1 (1.8-9.0)
95.9 (91.098.2)

0.01
4
10.8 (7.2-15.8)
89.2 (84.292.8)
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17.3 (12.423.6)
82.7 (76.487.6)

0.03
6
25.7 (19.533.1)
74.3 (66.980.5)

0.61
65.9 (50.778.4)
34.1 (21.649.0)

0.81
63.0 (51.573.2)
37.0 (26.848.4)

0.13
12.7 (8.917.9)
30.1 (23.737.3)
29.5 (23.736.2)
27.7 (22.433.6)

0.12
17.4 (12.723.3)
29.5 (23.836.0)
27.4 (22.233.2)
25.8 (20.931.3)
0.83

0.04
1
35.7 (29.742.2)
46.0 (38.352.0)
15.9 (11.022.5)
3.3 (1.6-7.0)
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24.2 (19.429.7)
42.5 (36.448.9)
28.4 (22.535.0)
4.9 (2.9-8.1)

Table 3. Difference in selected demographic characteristics in Louisiana and
Alabama, in Louisiana and Mississippi, post-policy period
Characteristics

Louisiana
(n=598 )
%(95% CI)

Alabama
(n=487 )
%(95% CI)

52.4 (48.156.6)
47.6 (43.451.9)

59.2 (54.563.7)
40.8 (36.345.5)

4.6 (3.2-6.6)
51.3 (47.255.4)
38.5 (34.442.8)
5.5 (3.9-7.8)

4.6 (3.0-6.9)
57.7 (53.162.1)
33.3 (28.938.0)
4.5(3.2-6.2)

61.3 (57.265.3)
38.7 (34.742.8)

58.7 (54.363.0)
41.3 (37.045.7)

Vaccinated
No
Yes
Race and ethnicity
Hispanic
Non-Hispanic
White
Non-Hispanic
Black
Other
Teen's age
13-15years
16-17 years
No. of medical
visits last year
1 to 3
4 to 6
7 to 9
Ever been
uninsured since
age 11
Yes
No
HPV vaccine
recommendation
No
Yes

pvalue
0.03

Mississippi
(n=529 )
%(95% CI)

70.8(66.8-74.6)
29.2 (25.433.2)
0.2

0.006
2.2 (1.3-3.7)
48.2 (44.052.5)
46.3 (42.050.6)
3.3 (2.0-5.2)

0.39

0.88
60.9 (56.664.9)
39.1 (35.143.4)

0.09
72.5 (68.576.1)
20.8 (17.524.5)
6.7 (4.8-9.2)

75.9 (72.079.4)
30.2 (16.934.0)
3.9 (2.7-5.5)

0.039
77.6 (74.080.9)
18.6 (15.622.1)
3.7 (2.6-5.4)

0.27

5.7 (3.8-8.5)
94.3 (91.596.2)

7.8 (5.3-11.4)
92.2 (88.694.7)

0.02

10.4 (7.6-14.0)
89.6 (86.092.4)
0.68

48.1(43.052.3)
51.9 (47.756.1)

46.8 (42.351.3)
53.2 (48.757.7)

87

pvalue
0.000
1

0.000
1
59.9 (55.764.0)
40.1 (36.044.4)

Age at last
medical visits
Less than 11 years
11 years or older

0.23
3.2 (2.3-4.6)
96.8 (95.497.7)

Teen had 11-12
year-old medical
check-up?
No 11.7 (8.9-15.2)
Yes
88.3 (84.891.1)
Marital status of
mother
Married 58.0 (53.862.1)
Not married
42.0 (37.946.3)
Mother's
education level
Less than high
14.0 (11.0school
17.5)
High school
33.5 (29.537.8)
Some College 25.2 (22.1128.6)
College graduate
27.3 (24.130.7)
Household
income
Above poverty
28.0 (24.9>$75,000
31.3)
Above poverty
39.0 (35.0<= $75,000
43.0)
Below poverty
28.7 (24.6level
33.0)
Unknown 4.4 (3.2-6.1)

4.5 (3.0-6.7)
95.5 (93.397.5)

0.000
1
8.2 (6.3-10.5)
91.8 (89.593.7)

0.24

9.1 (6.7-12.4)
90.9 (87.693.3)

0.03

11.7 (8.9-15.2)
88.3 (84.891.1)
0.78

58.9 (54.363.3)
41.1 (36.745.7)

0.59
56.3 (51.960.6)
43.7 (39.448.1)

0.21
14.3 (11.417.9)
28.0 (23.932.5)
25.7 (22.329.7)
32.0 (28.435.9)

0.075
12.4 (9.6-15.7)
27.6 (23.831.8)
30.8 (27.034.9)
29.2 (25.832.9)

0.23
29.6 (26.133.2)
37.0 (32.941.4)
26.4 (22.330.9)
7.0 (5.1-9.5)
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0.051
21.9 (19.125.0)
39.2 (35.143.4)
34.6 (30.339.1)
4.3 (3.1-6.0)

Table 4. Odds ratios for HPV vaccination according to selected characteristics,
Louisiana and Alabama, and Louisiana and Mississippi
Characteristi
cs
Policy
implemented
No
Yes

Louisiana and Alabama
Model 1
Model 2
(n=2162)
(n=949)
aOR (95%CI) aOR (95%CI)

Ref.
1.04 (0.771.4)

Ref.
0.80 (0.44-1.4)

Louisiana and Mississippi
Model 1
Model 2
(n=2,305)
(n=936)
aOR (95%CI)
aOR (95%CI)

Ref.
2.01 (1.472.8)***

Ref.
1.50 (0.81-2.8)

Ref.
2.0 (1.42.77)***

Ref.
1.46 (0.81-2.6)

1.12 (0.72-1.8)

1.41 (0.64-3.1)

Period
Pre
Post
Interaction
term
Policy*period
HPV vaccine
recommendati
on
No
Yes
Race and
ethnicity
Non-Hispanic
White
Hispanic
Non-Hispanic
Black
Other
Mother's
education
level
Less than high
school
High school
Some College
College
graduate

Ref.
1.60 (1.22.6)**

1.41 (0.902.2)

Ref.
1.21 (0.73-2.0)

1.80 (0.86-3.8)

Ref.
7.74(5.2215)***

Ref.
1.08 (0.49-2.4)
0.58 (0.370.9)*
1.21 (0.50-2.9)

Ref.
0.99 (0.51-1.9)
1.5(0.78-2.9)
1.31 (0.64-2.6)
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Ref.
7.05 (4.610.7)***

Ref.
1.37 (0.45-4.1)
0.68 (0.43-1.1)
1.62 (0.50-5.3)

Ref.
1.13(0.55-2.3)
1.36 (0.66-2.8)
1.45 (0.65-3.3)

Household
income
Above poverty
>$75,000
Above poverty
<= $75,000
Below poverty
level
Unknown
No. of medical
visits last year
1 to 3
4 to 6
7 to 9
Ever been
uninsured
since age 11
Yes
No
Mother's
marital status
Married
Not married
Teen's age
13-15 years
16-17 years
Teen had 1112 year-old
check-up?
Yes
No
* p<0.05; ** p<0.01; *** p<0.001

Ref.
1.55 (0.96-2.5)

Ref.
1.29 (0.77-2.2)

2.44 (1.254.8)**
1.23 (0.53-2.9)

1.72 (0.78-3.8)

Ref.
1.39 (0.90-2.1)
2.84 (1.322.9)**

Ref.
1.30 (0.80-2.1)
2.24 (0.97-5.2)

Ref.
1.41 (0.75-2.7)

Ref.
1.64 (0.78-3.4)

Ref.
1.26 (0.82-1.9)

Ref.
1.11 (0.71-1.7)

Ref.
1.08 (0.76-1.5)

Ref.
0.95 (0.65-1.4)

Ref.
0.91 (0.51-1.6)

Ref.
1.2 (0.64-2.2)
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2.6 (0.91-5.6)

Figure 4. Physician recommendation trends in Louisiana and Alabama, and
Mississippi, 2008-2012
Trends in Physician recommendation in Louisiana,
Alabama, and Mississippi, 2008-2012
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Table 5. Difference-in-differences estimates for physician recommendation
proportions in Louisiana and Alabama, Louisiana and Mississippi
N= 2,218
Louisiana
Alabama

Pre-policy period Post-policy period Difference
(2008-09)
(2011-12)
0.47
0.557
0.087
0.461

0.551

0.09
0.003

DiD
N= 2,343
Louisiana

0.47

0.557

0.087***

Mississippi

0.315

0.454

0.139***
0.052

DiD
* p<0.05; ** p<0.01; *** p<0.001
DiD= difference-in-differences
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Table 6. Odds ratios for HPV vaccine recommendation according to selected
characteristics, Louisiana and Alabama, Louisiana and Mississippi
Louisiana and Alabama
Model 1
Model 2 (
(N=2,227)
N=1,007)
aOR
aOR
(95%CI)
(95%CI)

Louisiana and Mississippi
Model 1
Model 2
(N=2,375)
(N=998)
aOR
aOR
(95%CI)
(95%CI)

No
Yes

Ref.
1.04 (0.781.38)

Ref.
1.11 (0.661.87)

Ref.
1.93 (1.452.6)***

Ref.
1.81 (1.053.1)*

Pre
Post

Ref.
1.44 (1.061.95)*

Ref.
1.23(0.762.0)

Ref.
1.80 (1.352.4)***

Ref.
1.34 (0.812.2)

0.99 (0.641.51)

1.09 (0.562.1)

0.79 (0.521.2)

0.99 (0.492.0)

Characteristics

Policy implemented

Period

Interaction term
Policy*period
Race and ethnicity
Non-Hispanic White
Hispanic
Non-Hispanic Black
Other
Mother's education
level
Less than high school
High school
Some College
College graduate
Household income
Above poverty
>$75,000
Above poverty
<= $75,000
Below poverty level

Ref.
1.71(0.714.2)
1.05 (0.422.6)
1.49 (0.504.4)

Ref.
1.10 (0.403.0)
0.77 (0.271.3)
1.09 (0.304.0)

Ref.
1.17 (0.642.1)
1.95 (1.063.6)*
2.80 (1.475.4)**

Ref.
1.13 (0.582.2)
2.1 (1.074.1)*
2.3 (1.154.6)

Ref.

Ref.

0.92 (0.601.4)
1.00 (0.561.8)

0.90(0.591.4)
0.76(0.421.4)

92

Unknown
No. of medical visits
last year
1 to 3
4 to 6
7 to 9
Ever been uninsured
since age 11?
Yes
No
Mother's marital status
Married
Not married

0.99 (0.442.2)

1.44 (0.583.5)

Ref.
1.05 (0.711.6)
0.40 (0.210.78)**

Ref.
1.12 (0.731.8)
0.70 (0.351.4)

Ref.
1.17 (0.641.6)

Ref.
0.93 (0.491.8)

Ref.
1.22 (0.821.8)

Ref.
1.19 (0.781.8)

Ref.
1.04 (0.751.5)

Ref.
1.02 (0.711.5)

Ref.
0.52 (0.300.90)*

Ref.
0.48 (0.280.8)**

Teen's age
13-15 years
16-17 years
Teen had an 11-12
year-old check-up?
Yes
No
* p<0.05; ** p<0.01; *** p<0.001
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Conclusion
This dissertation sought to provide an estimation of HPV infection in the South as
compared to the rest of the country to highlight the geographic variation in the United
States. It was hypothesized that the prevalence of infection from oncogenic HPV types
would be higher in the South compared to the rest of the country. Although this
hypothesis was not true for females aged 14 ̶ 26 years, it was true for females 27 ̶ 59 years
old. Moreover, this dissertation sought to evaluate two HPV vaccination policies that
could serve as prototypes for Southern states. It was hypothesized that HPV vaccination
rates would be significantly higher in the period after the policy was implemented
compared with the period preceding the implementation of both Virginia’s and
Louisiana’s policy. Findings indicated that neither of the two policies have resulted in an
increase in vaccination rates.
Several policy analysis frameworks were considered for the theoretical
framework of the study. Since the study included a problem identification and a policy
evaluation components, Lasswell’s Stages Heuristic Public Policy Framework (Lasswell,
1956) was selected. Lasswell’s theory is among the most well-known public policy
theories. He identified four stages in the public policy process: agenda setting,
formulation, implementation, and evaluation. The agenda setting is the stage in which a
social problem issue is identified. In the formulation stage, legislators or policy-makers
design, introduce, and enact a policy to resolve the social problem previously identified.
In the implementation stage, the policies are carried out, and in the evaluation stage, the
impact of the policy is assessed (Lasswell, 1956). Lasswell’s Stages Heuristic Public
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Policy theory presumes a linear process, thereby oversimplifying the complexity of
public policy process. This theory has been widely criticized, particularly for its
presumption of a linear policy process (Sabatier, 2007). Nonetheless, the Lasswell’s
Stages Heuristic approach encompasses the entire public policy process, which provides a
wide framework to situate this research.
The conceptual framework of this dissertation was founded upon the Linking
Health-related Policy to Health Systems and Outcomes framework (Hardee, Irani,
Maclnnis, & Hamilton, 2012). The Linking Health-Related Policy to Health Systems and
Outcomes framework was based on Lasswell’s Stages Heuristic theory and included the
four stages. Linking Health-Related Policy to Health Systems and Outcomes includes
seven principal components: enabling environment, health-related policy development,
health policy and program implementation, health systems and health outcomes, policy
monitoring, program monitoring, policy and program evaluation (Hardee et al., 2012).
Linking Health-Related Policy to Health Systems and Outcomes framework considers an
enabling environment that includes two aspects. The first aspect of the enabling
environment includes factors such as political stability, government effectiveness, and
accountability. The second aspect includes political, socio-cultural, and economic factors
that may facilitate or hinder the policy implementation. It is in such an enabling
environment that effective public policies can be developed and implemented because it
dictates not only the development and implementation, but also the impact of the policy.
The influence of the social, political, and economic factors on the implementation and
effectiveness of the policy were considered. Additionally, the model considers the
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problem identification and the health outcome that the policy is intended to influence
(Hardee et al., 2012). Pertaining to this study, several cancers result from HPV infection,
but for Southern states, cervical cancer disparities was the central health concern guiding
HPV vaccination policies. Furthermore, Hardy and colleagues pointed out that the
evaluation may quantify the adoption of a health behavior by the intended population
(Hardee et al., 2012). Relating to this study, HPV vaccination is the healthy behavior
whose adoption was quantified.
The dissertation had a few limitations. The first limitation is the use of selfreported data in all three manuscripts. Self-reported data are subject to recall bias. This
bias may have decreased the internal validity of the study. The data used for the
dissertation were also subject to social desirability bias, particularly for sexual risk
behaviors. Sexual behavior variables were collected using ACASI questionnaires rather
than face-to-face interviews. ACASI minimizes social desirability bias. The residual
desirability bias may have resulted in an underrepresentation of sexual risk behaviors,
thereby reducing study internal validity. Regarding the policy analysis component,
although the comparison states share regional characteristics with the policy or treatment
states, they were not identical. Moreover, the collection of some variables previously
included the NIS-Teen discontinued after 2009. As a result, they could not be included in
the policy analysis. One such variable was HPV or HPV vaccine knowledge. Had this
variable been collected for all survey years included in the analysis, the change in HPV or
HPV vaccine awareness could have been assessed for the treatment or policy states.
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Major Findings
Despite these limitations, the dissertation filled several important gaps in the
literature and produced the following findings:
o The prevalence of infection from high-risk HPV types was higher among
females aged 27 ̶ 59 years in the South compared to their counterparts in
the rest of the country.
o

The prevalence infection with oncogenic HPV types was higher among
females aged 27 ̶ 59 years in the South compared to their counterparts in
the rest of the country.

o Having more than four lifetime sex partners was associated with HPV
infections.
o Women who were sexually active and unmarried had higher odds of HPV
infections compared with those who were married.
o Virginia’s HPV vaccine mandate for school-entry may not have resulted in
a significant increase in HPV vaccination among adolescent females.
o In Virginia, physician recommendation remained strongly associated with
HPV vaccination in spite of the implementation of the mandate.
o Louisiana’s HPV/HPV vaccinate awareness policy may not have led to a
significant increase in HPV vaccination when compared with states
without such a policy.
o Physician recommendation was strongly associated with HPV vaccination
in Louisiana in spite of the parental awareness policy.
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Public Health and Policy Implications
Despite the availability of cervical cancer screening in the United States, the
South continues to experience cervical cancer disparities. HPV infection from high-risk
types are higher in the South among women aged 27 years and above. To reduce
disparities in cervical cancer incidence and mortality, public health efforts to increase
cervical cancer screening in the South must continue. We must not only strive to achieve
Healthy People 2020’s projected screening goal of 93%, but we must also ensure that
screening services are accessible to women who are least likely to be screened.
Particularly among Southern women, cervical cancer screening services should be made
accessible to those with less than high school education, those living at 200% or below
the federal poverty level (National Institute of Health, 2015), and those living in rural
areas (Doescher & Jackson, 2009). Additionally, the rates of HPV infection are relatively
high among 14 ̶ 26 year-old females, which highlights the importance of vaccinating preteens against HPV.
The policy impact evaluation component of the dissertation was intended to
facilitate evidence-based HPV vaccination policy-making. The effectiveness of a health
policy depends generally on sociocultural, political, and economic factors, among others.
HPV vaccination policies are not exceptional. The public perception of a policy, which
depends, in part, on the media coverage, may have a considerable influence on its
acceptance. In the case of Virginia’s HPV vaccine mandate for school-entry, the media
coverage was not consistent or generally positive. Additionally, parents perceived the
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mandate as an infringement on their rights. Such an unfavorable environment likely
reduced parental compliance to the mandate.
HPV vaccine awareness policies did not receive negative media coverage.
However, HPV vaccination awareness alone was insufficient to lead to HPV vaccination.
There are several factors that create a chasm between parental HPV vaccine awareness
and getting the adolescent vaccinated. These barriers include lack of transportation, outof-pocket cost, parental consent, safety concerns, and parental concerns that the vaccine
will promote sexual promiscuity. Uniform and consistent HPV information should be
delivered to parents in order for them to understand the reasons the vaccine is needed.
Furthermore, HPV vaccine awareness prepares parents and adolescents for physician
recommendation and to ask pertinent questions to healthcare providers. Therefore, HPV
vaccine awareness policies should be encouraged.
Physician recommendation remains the principal factor associated with HPV
vaccination. As a result, policy-makers should consider policies that may increase
physician recommendation. State should introduce bills to fund HPV education and best
practices regarding vaccine recommendation for current and future physicians.
Additionally, similar trainings should be funded for and provided to other medium-level
healthcare providers such as nurse practitioners and physician assistants, particularly
those practicing in areas with cervical cancer disparities.
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Directions for Future Research
The findings indicate a higher prevalence of HPV infection from high-risk types
in the American South. Further studies are needed to help understand and eliminate
barriers to cervical cancer screening in the South. We did not find evidence that
Virginia’s vaccine mandate or Louisiana’s HPV education policy led to an increase in
vaccination among females aged 13 ̶ 17 years. However, it found a strong association
between physician recommendation and vaccination. Despite these important findings,
the research could not point out all the factors that could dilute the impact of Louisiana’s
HPV vaccination awareness or Virginia’s HPV vaccine mandate for school-entry.
Investigations focusing on parental views as well as physician’s views of state policies
are needed to better understand the socio-cultural contexts in which these policies may be
effective. Moreover, since physician recommendation is the factor most strongly
associated with vaccination, efforts to encourage physician recommendation must
continue along with research to better understand its facilitators. Furthermore, additional
studies should investigate the role of nurses and physician assistants in facilitating
physician recommendation.
The dissertation supplied evidence coherent with the higher rates of cervical
cancer in the American South. Furthermore, it has evaluated the impact of a HPV
awareness policy as well as a HPV vaccine mandate. Although findings of this research
indicated a higher prevalence of high-risk oncogenic HPV types among Southern women
aged 27 ̶ 59, it could not elucidate the causes for the geographic disparities in HPV
infection. Further research may be needed to understand whether causal factors for these
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differences are modifiable. Moreover, the research could not point out all the factors that
hindered the effectiveness of Louisiana’s HPV vaccination awareness or Virginia’s
mandate. Investigations focusing on parental views as well as physician’s views of their
state policies are needed to better understand the socio-cultural contexts in which these
policies may be effective.
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